1,046 results on '"Indolfi C"'
Search Results
2. Vitamin D and asthma in children: insights from total and free 25-hydroxyvitamin D and vitamin D binding protein measurements
- Author
-
Allegorico, A., primary, Ruggiero, L., additional, Capristo, C., additional, Parisi, G., additional, Indolfi, C., additional, Umano, G.R., additional, Vuilleumier, P., additional, Dinardo, G., additional, and Miraglia del Giudice, M., additional
- Published
- 2023
- Full Text
- View/download PDF
3. Cardiovascular Magnetic Resonance in Patients with Cardiac Electronic Devices: Evidence from a Multicenter Study
- Author
-
Barison, A, Ricci, F, Pavon, A, Muscogiuri, G, Bisaccia, G, Camastra, G, De Lazzari, M, Lanzillo, C, Raguso, M, Monti, L, Vargiu, S, Pedrotti, P, Piacenti, M, Todiere, G, Pontone, G, Indolfi, C, Dellegrottaglie, S, Lombardi, M, Schwitter, J, Aquaro, G, Barison A., Ricci F., Pavon A. G., Muscogiuri G., Bisaccia G., Camastra G., De Lazzari M., Lanzillo C., Raguso M., Monti L., Vargiu S., Pedrotti P., Piacenti M., Todiere G., Pontone G., Indolfi C., Dellegrottaglie S., Lombardi M., Schwitter J., Aquaro G. D., Barison, A, Ricci, F, Pavon, A, Muscogiuri, G, Bisaccia, G, Camastra, G, De Lazzari, M, Lanzillo, C, Raguso, M, Monti, L, Vargiu, S, Pedrotti, P, Piacenti, M, Todiere, G, Pontone, G, Indolfi, C, Dellegrottaglie, S, Lombardi, M, Schwitter, J, Aquaro, G, Barison A., Ricci F., Pavon A. G., Muscogiuri G., Bisaccia G., Camastra G., De Lazzari M., Lanzillo C., Raguso M., Monti L., Vargiu S., Pedrotti P., Piacenti M., Todiere G., Pontone G., Indolfi C., Dellegrottaglie S., Lombardi M., Schwitter J., and Aquaro G. D.
- Abstract
Background: Most recent cardiac implantable electronic devices (CIEDs) can safely undergo a cardiovascular magnetic resonance (CMR) scan under certain conditions, but metal artifacts may degrade image quality. The aim of this study was to assess the overall diagnostic yield of CMR and the extent of metal artifacts in a multicenter, multivendor study on CIED patients referred for CMR. Methods: We analyzed 309 CMR scans from 292 patients (age 57 ± 16 years, 219 male) with an MR-conditional pacemaker (n = 122), defibrillator (n = 149), or loop recorder (n = 38); CMR scans were performed in 10 centers from 2012 to 2020; MR-unsafe implants were excluded. Clinical and device parameters were recorded before and after the CMR scan. A visual analysis of metal artifacts was performed for each sequence on a segmental basis, based on a 5-point artifact score. Results: The vast majority of CMR scans (n = 255, 83%) were completely performed, while only 32 (10%) were interrupted soon after the first sequences and 22 (7%) were only partly acquired; CMR quality was non-diagnostic in 34 (11%) scans, poor (<1/3 sequences were diagnostic) in 25 (8%), or acceptable (1/3 to 2/3 sequences were diagnostic) in 40 (13%), while most scans (n = 201, 68%) were of overall good quality. No adverse event or device malfunctioning occurred, and only nonsignificant changes in device parameters were recorded. The most affected sequences were SSFP (median score 0.32 [interquartile range 0.07–0.91]), followed by GRE (0.18 [0.02–0.59]) and LGE (0.14 [0.02–0.55]). ICDs induced more artifacts (median score in SSFP images 0.87 [0.50–1.46]) than PMs (0.11 [0.03–0.28]) or ILRs (0.11 [0.00–0.56]). Moreover, most artifacts were located in the anterior, anteroseptal, anterolateral, and apical segments of the LV and in the outflow tract of the RV. Conclusions: CMR is a versatile imaging technique, with a high safety profile and overall good image quality even in patients with MR-conditional CIEDs. Several stra
- Published
- 2023
4. Efficacy, safety, adherence and persistence of PCSK9 inhibitors in clinical practice: A single country, multicenter, observational study (AT-TARGET-IT)
- Author
-
Gargiulo, P, Basile, C, Cesaro, A, Marzano, F, Buonocore, D, Asile, G, Abbate, V, Vicidomini, F, Paolillo, S, Spaccarotella, C, Catalano, A, Spirito, G, Merlini, P, Maloberti, A, Iannuzzo, G, Ciccone, M, Zito, A, Paloscia, L, D'Alleva, A, Varbella, F, Corleto, A, Brunetti, N, Corbo, M, Calabro, P, Indolfi, C, Perrone-Filardi, P, Gargiulo P., Basile C., Cesaro A., Marzano F., Buonocore D., Asile G., Abbate V., Vicidomini F., Paolillo S., Spaccarotella C. A. M., Catalano A., Spirito G., Merlini P. A., Maloberti A., Iannuzzo G., Ciccone M. M., Zito A. P., Paloscia L., D'Alleva A., Varbella F., Corleto A., Brunetti N. D., Corbo M. D., Calabro P., Indolfi C., Perrone-Filardi P., Gargiulo, P, Basile, C, Cesaro, A, Marzano, F, Buonocore, D, Asile, G, Abbate, V, Vicidomini, F, Paolillo, S, Spaccarotella, C, Catalano, A, Spirito, G, Merlini, P, Maloberti, A, Iannuzzo, G, Ciccone, M, Zito, A, Paloscia, L, D'Alleva, A, Varbella, F, Corleto, A, Brunetti, N, Corbo, M, Calabro, P, Indolfi, C, Perrone-Filardi, P, Gargiulo P., Basile C., Cesaro A., Marzano F., Buonocore D., Asile G., Abbate V., Vicidomini F., Paolillo S., Spaccarotella C. A. M., Catalano A., Spirito G., Merlini P. A., Maloberti A., Iannuzzo G., Ciccone M. M., Zito A. P., Paloscia L., D'Alleva A., Varbella F., Corleto A., Brunetti N. D., Corbo M. D., Calabro P., Indolfi C., and Perrone-Filardi P.
- Abstract
Background and aims: Proprotein Convertase Subtilisin/Kexin type 9 inhibitors (PCSK9i) are recommended in patients at high and very-high cardiovascular (CV) risk, with documented atherosclerotic CV disease (ASCVD), and for very-high risk patients with familial hypercholesterolaemia not achieving LDL-cholesterol (LDL-C) goal while receiving maximally tolerated dose of lipid-lowering therapy (LLT). However, single country real-life data, reporting the use of PCSK9i in clinical practice, are limited. Therefore, we designed AT-TARGET-IT, an Italian, multicenter, observational registry on the use of PCSK9i in clinical practice. Methods: All data were recorded at the time of the first prescription and at the latest observation preceding inclusion in the study. Results: 798 patients were enrolled. The median reduction in LDL-C levels was 64.9%. After stratification for CV risk, 63.8% achieved LDL-C target; of them, 83.3% took LLTs at PCSK9i initiation and 16.7% did not. 760 patients (95.2%) showed high adherence to therapy, 13 (1.6%) partial adherence, and 25 (3.1%) poor adherence. At 6 months, 99.7% of patients enrolled in the study remained on therapy; there were 519 and 423 patients in the study with a follow-up of at least 12 and 18 months, respectively. Persistence in these groups was 98.1% and 97.5%, respectively. Overall, 3.5% of patients discontinued therapy. No differences in efficacy, adherence, and persistence were found between alirocumab and evolocumab. Conclusions: PCSK9i are safe and effective in clinical practice, leading to very high adherence and persistence to therapy, and achievement of recommended LDL-C target in most patients, especially when used as combination therapy.
- Published
- 2023
5. Razionale e valore fondamentale della Rete Italiana integrata dell’Amiloidosi Cardiaca [Rationale and significance of the Italian Network for Cardiac Amyloidosis]
- Author
-
Sinagra, G, Emdin, M, Merlo, M, Vergaro, G, Aimo, A, Biagini, E, Imazio, M, Porcari, A, Limongelli, G, Cipriani, A, Canepa, M, Musumeci, B, Cameli, M, Crotti, L, Di Bella, G, Di Lenarda, A, Cappelli, F, Chimenti, C, Obici, L, Iacoviello, M, Perlini, S, Pieroni, M, Metra, M, Oliva, F, Perrone Filardi, P, Colivicchi, F, Indolfi, C, Sinagra G., Emdin M., Merlo M., Vergaro G., Aimo A., Biagini E., Imazio M., Porcari A., Limongelli G., Cipriani A., Canepa M., Musumeci B., Cameli M., Crotti L., Di Bella G., Di Lenarda A., Cappelli F., Chimenti C., Obici L., Iacoviello M., Perlini S., Pieroni M., Metra M., Oliva F., Perrone Filardi P., Colivicchi F., Indolfi C., Sinagra, G, Emdin, M, Merlo, M, Vergaro, G, Aimo, A, Biagini, E, Imazio, M, Porcari, A, Limongelli, G, Cipriani, A, Canepa, M, Musumeci, B, Cameli, M, Crotti, L, Di Bella, G, Di Lenarda, A, Cappelli, F, Chimenti, C, Obici, L, Iacoviello, M, Perlini, S, Pieroni, M, Metra, M, Oliva, F, Perrone Filardi, P, Colivicchi, F, Indolfi, C, Sinagra G., Emdin M., Merlo M., Vergaro G., Aimo A., Biagini E., Imazio M., Porcari A., Limongelli G., Cipriani A., Canepa M., Musumeci B., Cameli M., Crotti L., Di Bella G., Di Lenarda A., Cappelli F., Chimenti C., Obici L., Iacoviello M., Perlini S., Pieroni M., Metra M., Oliva F., Perrone Filardi P., Colivicchi F., and Indolfi C.
- Abstract
The perspective on amyloidosis has changed deeply over the last 10 years following major advances in diagnosis and treatment options, especially in cardiac amyloidosis. This intrinsically heterogeneous disease exposes to the risk of fragmentation of knowledge and requires the interaction among experts of different specialties and subspecialties. Suspicion of disease, timely recognition and confirmation of final diagnosis, prognostic stratification, clinical management and therapeutic strategies represent essential steps to be taken. Missing or delaying the diagnosis may have dramatic impact on patient outcome, as in the case of chemotherapy in unrecognized light-chain amyloidosis. Therefore, there is an urgent need for the foundation of an Italian Amyloidosis Network to deal with the challenges of this condition and orient clinical management at national and local levels. The present consensus document aims to provide the rationale and scopes of the Italian Amyloidosis Network, which has been conceived as an organizational framework for professionals managing patients with amyloidosis.
- Published
- 2023
6. Efficacy, safety, adherence and persistence of PCSK9 inhibitors in clinical practice: a single country, multicenter, observational study (AT-TARGET-IT)
- Author
-
Gargiulo, P, primary, Basile, C, additional, Calabro', P, additional, Catalano, A, additional, Merlini, P A, additional, Iannuzzo, G, additional, Ciccone, M M, additional, Paloscia, L, additional, Varbella, F, additional, Brunetti, N D, additional, Paolillo, S, additional, Marzano, F, additional, Indolfi, C, additional, and Perrone-Filardi, P, additional
- Published
- 2023
- Full Text
- View/download PDF
7. Efficacy and safety of inclisiran in real world practice: insights from the Cholinet registry
- Author
-
Basile, C, primary, Gargiulo, P, additional, Merlini, P A, additional, Brunetti, N D, additional, Musumeci, G, additional, Casu, G, additional, Galasso, G, additional, Varbella, F, additional, Calabro', P, additional, Ciccone, M M, additional, Calo', L, additional, Bilato, C, additional, Paolillo, S, additional, Indolfi, C, additional, and Perrone-Filardi, P, additional
- Published
- 2023
- Full Text
- View/download PDF
8. Use of inclisiran in a real-world setting: results from the italian Cholinet registry
- Author
-
Basile, C, primary, Gargiulo, P, additional, Indolfi, C, additional, Brunetti, N D, additional, Musumeci, G, additional, Casu, G, additional, Galasso, G, additional, Varbella, F, additional, Cesaro, A, additional, Patti, G, additional, Carugo, S, additional, Marzano, F, additional, Paolillo, S, additional, Merlini, P A, additional, and Perrone-Filardi, P, additional
- Published
- 2023
- Full Text
- View/download PDF
9. Quantification of heart failure decompensation through mixed digital methodology
- Author
-
Romano, L, primary, Curcio, A, additional, Scalzi, G, additional, Malizia, B, additional, Festa, M, additional, and Indolfi, C, additional
- Published
- 2023
- Full Text
- View/download PDF
10. One-month dual antiplatelet therapy following stent implantation in patients with acute coronary syndromes and high bleeding risk
- Author
-
Pivato, C A, primary, Musto, C, additional, Paolucci, L, additional, Testa, L, additional, Pacchioni, A, additional, Briguori, C, additional, Esposito, G, additional, Lucisano, L, additional, De Luca, L, additional, Latini, A C, additional, Regazzoli, D, additional, Sardella, G, additional, Indolfi, C, additional, Condorelli, G, additional, and Stefanini, G G, additional
- Published
- 2023
- Full Text
- View/download PDF
11. Razionale e valore fondamentale della Rete Italiana integrata dell’Amiloidosi Cardiaca [Rationale and significance of the Italian Network for Cardiac Amyloidosis]
- Author
-
Sinagra G., Emdin M., Merlo M., Vergaro G., Aimo A., Biagini E., Imazio M., Porcari A., Limongelli G., Cipriani A., Canepa M., Musumeci B., Cameli M., Crotti L., Di Bella G., Di Lenarda A., Cappelli F., Chimenti C., Obici L., Iacoviello M., Perlini S., Pieroni M., Metra M., Oliva F., Perrone Filardi P., Colivicchi F., Indolfi C., Sinagra, G, Emdin, M, Merlo, M, Vergaro, G, Aimo, A, Biagini, E, Imazio, M, Porcari, A, Limongelli, G, Cipriani, A, Canepa, M, Musumeci, B, Cameli, M, Crotti, L, Di Bella, G, Di Lenarda, A, Cappelli, F, Chimenti, C, Obici, L, Iacoviello, M, Perlini, S, Pieroni, M, Metra, M, Oliva, F, Perrone Filardi, P, Colivicchi, F, and Indolfi, C
- Subjects
Treatment ,Clinical management ,Cardiac amyloidosi ,Differential diagnosi ,Perspective - Abstract
The perspective on amyloidosis has changed deeply over the last 10 years following major advances in diagnosis and treatment options, especially in cardiac amyloidosis. This intrinsically heterogeneous disease exposes to the risk of fragmentation of knowledge and requires the interaction among experts of different specialties and subspecialties. Suspicion of disease, timely recognition and confirmation of final diagnosis, prognostic stratification, clinical management and therapeutic strategies represent essential steps to be taken. Missing or delaying the diagnosis may have dramatic impact on patient outcome, as in the case of chemotherapy in unrecognized light-chain amyloidosis. Therefore, there is an urgent need for the foundation of an Italian Amyloidosis Network to deal with the challenges of this condition and orient clinical management at national and local levels. The present consensus document aims to provide the rationale and scopes of the Italian Amyloidosis Network, which has been conceived as an organizational framework for professionals managing patients with amyloidosis.
- Published
- 2023
12. Role of continuous glucose monitoring in diabetic patients at high cardiovascular risk: an expert-based multidisciplinary Delphi consensus
- Author
-
Di Mario, C, Genovese, S, Lanza, G, Mannucci, E, Marenzi, G, Sciatti, E, Pitocco, D, Avogaro, A, Bertuzzi, F, Bonora, E, Borghi, C, Buzzetti, R, Carugo, S, Capodanno, D, Consoli, A, Conti, A, Danesi, R, Bartolo, P, Ferrari, G, Favale, S, Giorda, C, Giorgino, F, Girelli, A, Golino, P, Grigioni, F, Indolfi, C, Irace, C, Lovati, E, Maffettone, A, Masulli, M, Oliva, F, Oltrona Visconti, L, Orsi, E, Pagotto, U, Paloscia, L, Parati, G, Perrone, P, Piccirillo, G, Pozzilli, P, Pugliese, G, Purrello, F, Ribichini, F, Rubboli, A, Senni, M, Trevisan, R, Tubili, C, Uguccioni, M, Di Mario C., Genovese S., Lanza G. A., Mannucci E., Marenzi G., Sciatti E., Pitocco D., Avogaro A., Bertuzzi F., Bonora E., Borghi C., Buzzetti R., Carugo S., Capodanno D., Consoli A., Conti A., Danesi R., Bartolo P., Ferrari G. M. D., Favale S., Giorda C., Giorgino F., Girelli A., Golino P., Grigioni F., Indolfi C., Irace C., Lovati E., Maffettone A., Masulli M., Oliva F. G., Oltrona Visconti L., Orsi E., Pagotto U., Paloscia L., Parati G., Perrone P., Piccirillo G., Pozzilli P., Pugliese G., Purrello F., Ribichini F., Rubboli A., Senni M., Trevisan R., Tubili C., Uguccioni M., Di Mario, C, Genovese, S, Lanza, G, Mannucci, E, Marenzi, G, Sciatti, E, Pitocco, D, Avogaro, A, Bertuzzi, F, Bonora, E, Borghi, C, Buzzetti, R, Carugo, S, Capodanno, D, Consoli, A, Conti, A, Danesi, R, Bartolo, P, Ferrari, G, Favale, S, Giorda, C, Giorgino, F, Girelli, A, Golino, P, Grigioni, F, Indolfi, C, Irace, C, Lovati, E, Maffettone, A, Masulli, M, Oliva, F, Oltrona Visconti, L, Orsi, E, Pagotto, U, Paloscia, L, Parati, G, Perrone, P, Piccirillo, G, Pozzilli, P, Pugliese, G, Purrello, F, Ribichini, F, Rubboli, A, Senni, M, Trevisan, R, Tubili, C, Uguccioni, M, Di Mario C., Genovese S., Lanza G. A., Mannucci E., Marenzi G., Sciatti E., Pitocco D., Avogaro A., Bertuzzi F., Bonora E., Borghi C., Buzzetti R., Carugo S., Capodanno D., Consoli A., Conti A., Danesi R., Bartolo P., Ferrari G. M. D., Favale S., Giorda C., Giorgino F., Girelli A., Golino P., Grigioni F., Indolfi C., Irace C., Lovati E., Maffettone A., Masulli M., Oliva F. G., Oltrona Visconti L., Orsi E., Pagotto U., Paloscia L., Parati G., Perrone P., Piccirillo G., Pozzilli P., Pugliese G., Purrello F., Ribichini F., Rubboli A., Senni M., Trevisan R., Tubili C., and Uguccioni M.
- Abstract
Background: Continuous glucose monitoring (CGM) shows in more detail the glycaemic pattern of diabetic subjects and provides several new parameters (“glucometrics”) to assess patients’ glycaemia and consensually guide treatment. A better control of glucose levels might result in improvement of clinical outcome and reduce disease complications. This study aimed to gather an expert consensus on the clinical and prognostic use of CGM in diabetic patients at high cardiovascular risk or with heart disease. Methods: A list of 22 statements concerning type of patients who can benefit from CGM, prognostic impact of CGM in diabetic patients with heart disease, CGM use during acute cardiovascular events and educational issues of CGM were developed. Using a two-round Delphi methodology, the survey was distributed online to 42 Italian experts (21 diabetologists and 21 cardiologists) who rated their level of agreement with each statement on a 5-point Likert scale. Consensus was predefined as more than 66% of the panel agreeing/disagreeing with any given statement. Results: Forty experts (95%) answered the survey. Every statement achieved a positive consensus. In particular, the panel expressed the feeling that CGM can be prognostically relevant for every diabetic patient (70%) and that is clinically useful also in the management of those with type 2 diabetes not treated with insulin (87.5%). The assessment of time in range (TIR), glycaemic variability (GV) and hypoglycaemic/hyperglycaemic episodes were considered relevant in the management of diabetic patients with heart disease (92.5% for TIR, 95% for GV, 97.5% for time spent in hypoglycaemia) and can improve the prognosis of those with ischaemic heart disease (100% for hypoglycaemia, 90% for hyperglycaemia) or with heart failure (87.5% for hypoglycaemia, 85% for TIR, 87.5% for GV). The experts retained that CGM can be used and can impact the short- and long-term prognosis during an acute cardiovascular event. Lastly, CGM has a
- Published
- 2022
13. Position paper of the Italian Society of Cardiology: The renin-angiotensin-aldosterone system (RAAS) blockade in heart failure patients - Part I: From RAAS identification to clinical trials [Position paper della Società Italiana di Cardiologia: Il blocco del sistema renina-angiotensina-aldosterone (RAAS) nel paziente con scompenso cardiaco – Parte I: Dalla scoperta del RAAS ai trial clinici]
- Author
-
Filardi, P, Paolillo, S, Indolfi, C, Agostoni, P, Basso, C, Barilla, F, Correale, M, Curcio, A, Mancone, M, Merlo, M, Metra, M, Muscoli, S, Nodari, S, Palazzuoli, A, Pedrinelli, R, Pontremoli, R, Senni, M, Volpe, M, Sinagra, G, Filardi P. P., Paolillo S., Indolfi C., Agostoni P., Basso C., Barilla F., Correale M., Curcio A., Mancone M., Merlo M., Metra M., Muscoli S., Nodari S., Palazzuoli A., Pedrinelli R., Pontremoli R., Senni M., Volpe M., Sinagra G., Filardi, P, Paolillo, S, Indolfi, C, Agostoni, P, Basso, C, Barilla, F, Correale, M, Curcio, A, Mancone, M, Merlo, M, Metra, M, Muscoli, S, Nodari, S, Palazzuoli, A, Pedrinelli, R, Pontremoli, R, Senni, M, Volpe, M, Sinagra, G, Filardi P. P., Paolillo S., Indolfi C., Agostoni P., Basso C., Barilla F., Correale M., Curcio A., Mancone M., Merlo M., Metra M., Muscoli S., Nodari S., Palazzuoli A., Pedrinelli R., Pontremoli R., Senni M., Volpe M., and Sinagra G.
- Abstract
L’inibizione del sistema renina-angiotensina-aldosterone (RAAS) rappresenta un caposaldo del trattamento farmacologico dello scompenso cardiaco a ridotta frazione di eiezione ed è stato potenziato dall’arrivo degli inibitori del recettore dell’angiotensina e della neprilisina (ARNI) che combinano l’inibizione del RAAS con l’inibizione della neprilisina responsabile di un incremento delle attività favorevoli dei peptidi natriuretici. Sacubitril/valsartan ha dimostrato nello studio PARADIGM-HF un netto vantaggio rispetto ad enalapril in termini di riduzione di mortalità ed ospedalizzazioni per insufficienza cardiaca e numerosi altri trial randomizzati e studi clinici ne hanno testato l’efficacia in differenti contesti. Dai risultati di questi studi è derivata la raccomandazione di classe I per l’utilizzo del farmaco in pazienti con frazione di eiezione ridotta. La prima parte di questo position paper esplora la storia dell’inibizione del RAAS per passare poi ad una dettagliata analisi dei risultati ottenuti negli studi clinici con gli ARNI che ne supportano le raccomandazioni delle più recenti linee guida., Renin-angiotensin-aldosterone (RAAS) system inhibition is a mainstay of the pharmacological treatment of heart failure with reduced ejection fraction and has been implemented by the introduction of angiotensin receptor-neprilysin inhibitors (ARNI), that combine RAAS inhibition with the inhibition of neprilysin, enhancing the favorable effects of natriuretic peptides. The PARADIGM-HF trial demonstrated a favorable effect of sacubitril/valsartan over enalapril in terms of mortality and heart failure hospitalization rate reduction. Then several randomized clinical trials and observational studies confirmed the favorable role of ARNI in different clinical scenarios, supporting the guideline class I recommendation for the use of sacubitrilvalsartan in patients with reduced systolic function. The first part of this position paper summarizes the history of RAAS inhibition and reports the results of ARNI trials that support the recommendations of the most recent guidelines.
- Published
- 2022
14. Position paper of the Italian Society of Cardiology: The renin-angiotensin-aldosterone system blockade in heart failure patients - Part II: Mechanistic effects of sacubitril/valsartan, placement in current guidelines and use in clinical practice [Position paper della Società Italiana di Cardiologia: Il blocco del sistema renina-angiotensina-aldosterone nel paziente con scompenso cardiaco – Parte II: Effetti meccanicistici di sacubitril/valsartan, posizionamento nelle linee guida ed utilizzo nella pratica clinica]
- Author
-
Filardi, P, Indolfi, C, Paolillo, S, Agostoni, P, Basso, C, Barilla, F, Correale, M, Curcio, A, Mancone, M, Merlo, M, Metra, M, Muscoli, S, Nodari, S, Palazzuoli, A, Pedrinelli, R, Pontremoli, R, Senni, M, Volpe, M, Sinagra, G, Filardi P. P., Indolfi C., Paolillo S., Agostoni P., Basso C., Barilla F., Correale M., Curcio A., Mancone M., Merlo M., Metra M., Muscoli S., Nodari S., Palazzuoli A., Pedrinelli R., Pontremoli R., Senni M., Volpe M., Sinagra G., Filardi, P, Indolfi, C, Paolillo, S, Agostoni, P, Basso, C, Barilla, F, Correale, M, Curcio, A, Mancone, M, Merlo, M, Metra, M, Muscoli, S, Nodari, S, Palazzuoli, A, Pedrinelli, R, Pontremoli, R, Senni, M, Volpe, M, Sinagra, G, Filardi P. P., Indolfi C., Paolillo S., Agostoni P., Basso C., Barilla F., Correale M., Curcio A., Mancone M., Merlo M., Metra M., Muscoli S., Nodari S., Palazzuoli A., Pedrinelli R., Pontremoli R., Senni M., Volpe M., and Sinagra G.
- Abstract
Il trattamento con sacubitril/valsartan ha assunto un ruolo di primo piano nelle ultime linee guida sia europee che americane, ed è attualmente raccomandato in classe I per il trattamento dei pazienti con ridotta frazione di eiezione. Accanto ai ben noti effetti sulla mortalità, sacubitril/valsartan agisce positivamente sulla riduzione dei valori di NT-proBNP e su parametri di rimodellamento ventricolare sinistro, determinando un rimodellamento inverso riconosciuto come uno degli effetti meccanicistici del farmaco atto a spiegare in parte il suo effetto favorevole sulla prognosi. Un’attenta valutazione del profilo di ogni singolo paziente consente un utilizzo più mirato e meglio tollerato del farmaco, garantendo anche in ambito di insufficienza cardiaca la strada della medicina di precisione. La seconda parte di questo position paper esplora gli effetti meccanicistici degli inibitori del recettore dell’angiotensina e della neprilisina e il loro posizionamento nelle linee guida, proponendo in ultima analisi un uso di sacubitril/valsartan in specifici contesti clinici., The use of sacubitril/valsartan has been fully recognized in the most recent European and American guidelines that recommend in class I the prescription of this drug in heart failure patients with reduced systolic function. Besides the effects on cardiovascular mortality and heart failure hospitalization, sacubitril/valsartan significantly reduces NT-proBNP levels and improves cardiac remodeling, recognized as one of the mechanistic effects of the drug that is linked to favorable prognostic effects. A careful evaluation of the patients' clinical profile is needed to implement the use of sacubitril/valsartan into clinical practice and to make the treatment successful. This second part of the position paper focuses on the mechanistic effects of angiotensin receptor-neprilysin inhibitors and on its placement in current guidelines, also suggesting the use of sacubitril/valsartan in specific clinical settings.
- Published
- 2022
15. Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan. Position Paper of the Italian Society of Cardiology
- Author
-
Perrone-Filardi, P, Paolillo, S, Agostoni, P, Basile, C, Basso, C, Barilla, F, Correale, M, Curcio, A, Mancone, M, Merlo, M, Metra, M, Muscoli, S, Nodari, S, Palazzuoli, A, Pedrinelli, R, Pontremoli, R, Senni, M, Volpe, M, Indolfi, C, Sinagra, G, Perrone-Filardi P., Paolillo S., Agostoni P., Basile C., Basso C., Barilla F., Correale M., Curcio A., Mancone M., Merlo M., Metra M., Muscoli S., Nodari S., Palazzuoli A., Pedrinelli R., Pontremoli R., Senni M., Volpe M., Indolfi C., Sinagra G., Perrone-Filardi, P, Paolillo, S, Agostoni, P, Basile, C, Basso, C, Barilla, F, Correale, M, Curcio, A, Mancone, M, Merlo, M, Metra, M, Muscoli, S, Nodari, S, Palazzuoli, A, Pedrinelli, R, Pontremoli, R, Senni, M, Volpe, M, Indolfi, C, Sinagra, G, Perrone-Filardi P., Paolillo S., Agostoni P., Basile C., Basso C., Barilla F., Correale M., Curcio A., Mancone M., Merlo M., Metra M., Muscoli S., Nodari S., Palazzuoli A., Pedrinelli R., Pontremoli R., Senni M., Volpe M., Indolfi C., and Sinagra G.
- Abstract
Renin-angiotensin-aldosterone system (RAAS) inhibition is a mainstay of the pharmacological treatment of heart failure with reduced ejection fraction (HFrEF). In the last years RAAS blockade has been improved by the introduction of the Angiotensin Receptor-Neprilysin Inhibitor (ARNI) sacubitril/valsartan, that combines RAAS inhibition with the block of neprilysin, boosting the positive effects of natriuretic peptides. The PARADIGM-HF trial demonstrated a significant advantage of sacubitril/valsartan over enalapril on the reduction of cardiovascular (CV) mortality and heart failure hospitalizations rates. Then, several randomized clinical trials and observational studies investigated its role in different clinical settings and its efficacy has been fully recognized in the most recent HFrEF European and USA guidelines. The effects of sacubitril/valsartan on major CV outcomes are associated with reduction of NT-proBNP levels and reverse cardiac remodeling and mitral regurgitation, recognized as one of the mechanistic effects of the drug explaining the favorable prognostic effects. A careful evaluation of patients’ clinical profile is relevant to implement the use of ARNI in the clinical practice and to obtain the maximal treatment efficacy. The present Position Paper reports the opinion of the Italian Society of Cardiology on the optimal blockade of the RAAS system in HF patients with the aim of fostering widespread implementation of scientific evidence and practice guidelines in the medical community.
- Published
- 2022
16. P288 TREATMENT OF HEART FAILURE IN CLINICAL PRACTICE: NON–INTERVENTIONAL OBSERVATIONAL STUDY ON PATIENTS WITH HEART FAILURE TREATED WITH DAPAGLIFLOZIN (EVOLUTION–HF ITALY)
- Author
-
Orso, F, primary, Ameri, P, additional, Carugo, S, additional, Di Lenarda, A, additional, Iacoviello, M, additional, Indolfi, C, additional, Mortara, A, additional, Perrone Filardi, P, additional, Ungar, A, additional, Volpe, M, additional, Volterrani, M, additional, Granelli, V, additional, Mastromauro, F, additional, Pluchinotta, F, additional, Gnesi, M, additional, and Rosano, G, additional
- Published
- 2023
- Full Text
- View/download PDF
17. Stent Thrombosis After Percutaneous Coronary Intervention: From Bare-Metal to the Last Generation of Drug-Eluting Stents
- Author
-
Polimeni A., Sorrentino S., Spaccarotella C., Mongiardo A., Sabatino J., De Rosa S., Gori T., Indolfi C., Polimeni, A., Sorrentino, S., Spaccarotella, C., Mongiardo, A., Sabatino, J., De Rosa, S., Gori, T., and Indolfi, C.
- Subjects
BMS ,BRS ,DES ,Stent ,Thrombosis ,Humans ,Percutaneous Coronary Intervention ,Polymers ,Prosthesis Design ,Absorbable Implants ,Drug-Eluting Stents ,Stents ,Absorbable Implant ,Metals ,Thrombosi ,Drug-Eluting Stent ,Polymer ,Human - Abstract
Since their introduction in clinical practice in 1986, different types of coronary stents have been developed and become available for the treatment of coronary artery disease. Stent thrombosis (ST) is an uncommon but harmful complication after percutaneous coronary implantation, with a high occurrence of acute myocardial infarction and risk of mortality. Among several procedural and clinical predictors, the type of coronary stent is a strong determinant of ST. This article reviews the available evidence on the most used coronary stent types in the modern era and the related risk of ST.
- Published
- 2022
18. Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice:: GLORIA-AF Registry
- Author
-
Lip G. Y. H., Kotalczyk A., Teutsch C., Diener H. -C., Dubner S. J., Halperin J. L., Ma C. -S., Rothman K. J., Marler S., Gurusamy V. K., Huisman M. V., Abban D. W., Aziz E., Kalan M. B., Abdul N., Backes L. M., Bradman D., Abud A. M., Badings E., Brautigam D., Adams F., Bagni E., Breton N., Addala S., Baker S. H., Brouwers P. J. A. M., Adragao P., Bala R., Browne K., Ageno W., Baldi A., Cortada J. B., Aggarwal R., Bando S., Bruni A., Agosti S., Banerjee S., Brunschwig C., Agostoni P., Bank A., Buathier H., Aguilar F., Esquivias G. B., Buhl A., Linares J. A., Barr C., Bullinga J., Aguinaga L., Bartlett M., Cabrera J. W., Ahmed J., Basic Kes V., Caccavo A., Aiello A., Baula G., Cai S., Ainsworth P., Behrens S., Caine S., Aiub J. R., Bell A., Calo L., Al-Dallow R., Benedetti R., Calvi V., Alderson L., Mazuecos J. B., Sanchez M. C., Velasco J. A. A., Benhalima B., Candeias R., Alexopoulos D., Bergler-Klein J., Capuano V., Manterola F. A., Berneau J. -B., Capucci A., Aliyar P., Bernstein R. A., Caputo R., Alonso D., Berrospi P., Rizo T. C., da Costa F. A. A., Berti S., Cardona F., Amado J., Berz A., da Costa Darrieux F. C., Amara W., Best E., Vera Y. C. D., Amelot M., Bettencourt P., Carolei A., Amjadi N., Betzu R., Carreno S., Ammirati F., Bhagwat R., Carvalho P., Andrade M., Bhatta L., Cary S., Andrawis N., Biscione F., Casu G., Annoni G., Bisignani G., Cavallini C., Ansalone G., Black T., Cayla G., Ariani M. K., Bloch M. J., Celentano A., Arias J. C., Bloom S., Cha T. -J., Armero S., Blumberg E., Cha K. S., Arora C., Bo M., Chae J. K., Aslam M. S., Bohmer E., Chalamidas K., Asselman M., Bollmann A., Challappa K., Audouin P., Bongiorni M. G., Chand S. P., Augenbraun C., Boriani G., Chandrashekar H., Aydin S., Boswijk D. J., Chartier L., Bott J., Chatterjee K., Ayryanova I., Bottacchi E., Ayala C. A. C., Cheema A., Davis G., Evonich R., Davy J. -M., Evseeva O., Chen L., Dayer M., Ezhov A., Chen S. -A., De Biasio M., Fahmy R., Chen J. H., De Bonis S., Fang Q., Chiang F. -T., De Caterina R., Farsad R., Chiarella F., De Franceschi T., Fauchier L., Chih-Chan L., de Groot J. R., Favale S., Cho Y. K., De Horta J., Fayard M., Choi J. -I., De La Briolle A., Fedele J. L., Choi D. J., de la Pena Topete G., Fedele F., Chouinard G., de Paola A. A. V., Fedorishina O., Chow D. H. -F., de Souza W., Fera S. R., Chrysos D., de Veer A., Ferreira L. G. G., Chumakova G., De Wolf L., Ferreira J., Valenzuela E. J. J. R. C., Decoulx E., Ferri C., Nica N. C., Deepak S., Ferrier A., Cislowski D. J., Defaye P., Ferro H., Clay A., Munoz F. D. -C., Finsen A., Clifford P., Brkljacic D. D., First B., Cohen A., Deumite N. J., Fischer S., Cohen M., Di Legge S., Fonseca C., Cohen S., Diemberger I., Almeida L. F., Colivicchi F., Dietz D., Forman S., Collins R., Dionisio P., Frandsen B., Colonna P., Dong Q., French W., Compton S., dos Santos F. R., Friedman K., Connolly D., Dotcheva E., Friese A., Conti A., Doukky R., Fruntelata A. G., Buenostro G. C., D'Souza A., Fujii S., Coodley G., Dubrey S., Fumagalli S., Cooper M., Ducrocq X., Fundamenski M., Coronel J., Dupljakov D., Furukawa Y., Corso G., Duque M., Gabelmann M., Sales J. C., Dutta D., Gabra N., Cottin Y., Duvilla N., Gadsboll N., Covalesky J., Duygun A., Galinier M., Cracan A., Dziewas R., Gammelgaard A., Crea F., Eaton C. B., Ganeshkumar P., Crean P., Eaves W., Gans C., Crenshaw J., Ebels-Tuinbeek L. A., Quintana A. G., Cullen T., Ehrlich C., Gartenlaub O., Darius H., Eichinger-Hasenauer S., Gaspardone A., Dary P., Eisenberg S. J., Genz C., Dascotte O., Jabali A. E., Georger F., Dauber I., Shahawy M. E., Georges J. -L., Davalos V., Hernandes M. E., Georgeson S., Davies R., Izal A. E., Giedrimas E., Gierba M., Haruna T., Jarmukli N., Ortega I. G., Hayek E., Jeanfreau R. J., Gillespie E., Healey J., Jenkins R. D., Giniger A., Hearne S., Sanchez C. J., Giudici M. C., Heffernan M., Jimenez J., Gkotsis A., Heggelund G., Jobe R., Glotzer T. V., Heijmeriks J. A., Joen-Jakobsen T., Gmehling J., Hemels M., Jones N., Gniot J., Hendriks I., Jorge J. C. M., Goethals P., Henein S., Jouve B., Goldbarg S., Her S. -H., Jung B. C., Goldberg R., Hermany P., Jung K. T., Goldmann B., Del Rio J. E. H., Jung W., Golitsyn S., Higashino Y., Kachkovskiy M., Gomez S., Hill M., Kafkala K., Mesa J. G., Hisadome T., Kalinina L., Gonzalez V. B., Hishida E., Kallmunzer B., Hermosillo J. A. G., Hoffer E., Kamali F., Lopez V. M. G., Hoghton M., Kamo T., Gorka H., Hong K., Kampus P., Gornick C., Hong S., Kashou H., Gorog D., Horbach S., Kastrup A., Gottipaty V., Horiuchi M., Katsivas A., Goube P., Hou Y., Kaufman E., Goudevenos I., Hsing J., Kawai K., Graham B., Huang C. -H., Kawajiri K., Greer G. S., Huckins D., Kazmierski J. F., Gremmler U., Hughes K., Keeling P., Grena P. G., Huizinga A., Saraiva J. F. K., Grond M., Hulsman E. L., Ketova G., Gronda E., Hung K. -C., Khaira A. S., Gronefeld G., Hwang G. -S., Khripun A., Gu X., Ikpoh M., Kim D. -I., Torres I. G. T., Imberti D., Kim Y. H., Guardigli G., Ince H., Kim N. H., Guevara C., Indolfi C., Kim D. K., Guignier A., Inoue S., Kim J. S., Gulizia M., Irles D., Gumbley M., Iseki H., Kim K. S., Gunther A., Israel C. N., Kim J., Ha A., Iteld B., Kinova E., Hahalis G., Iyer V., Klein A., Hakas J., Jackson-Voyzey E., Kmetzo J. J., Hall C., Jaffrani N., Kneller G. L., Han B., Jager F., Knezevic A., Han S., James M., Koh S. M. A., Hargrove J., Jang S. -W., Koide S., Hargroves D., Jaramillo N., Kollias A., Kooistra J. A., Li W., McClure J., Koons J., Li X., McCormack T., Koschutnik M., Lichy C., McGarity W., Kostis W. J., Lieber I., McIntyre H., Kovacic D., Rodriguez R. H. L., McLaurin B., Kowalczyk J., Lin H., Alvaro F., Palomino M., Koziolova N., Melandri F., Kraft P., Liu F., Meno H., Kragten J. A., Liu H., Menzies D., Krantz M., Esperon G. L., Mercader M., Krause L., Navarro N. L., Meyer C., Krenning B. J., Lo E., Meyer B. J., Krikke F., Lokshyn S., Miarka J., Kromhout Z., Lopez A., Mibach F., Krysiak W., Lopez-Sendon J. L., Michalski D., Kumar P., Filho A. M. L., Michel P., Kumler T., Lorraine R. S., Chreih R. M., Kuniss M., Luengas C. A., Luengas A., Mikdadi G., Kuo J. -Y., Luke R., Mikus M., Kuppers A., Luo M., Milicic D., Kurrelmeyer K., Lupovitch S., Militaru C., Kwak C. H., Lyrer P., Minaie S., Laboulle B., Ma C., Minescu B., Labovitz A., Ma G., Mintale I., Ter Lai W., Madariaga I., Mirault T., Lam A., Maeno K., Mirro M. J., Lam Y. Y., Magnin D., Mistry D., Lanas Zanetti F., Maid G., Miu N. V., Landau C., Mainigi S. K., Miyamoto N., Landini G., Makaritsis K., Moccetti T., Lanna Figueiredo E., Malhotra R., Mohammed A., Larsen T., Manning R., Nor A. M., Lavandier K., Manolis A., Mollerus M., LeBlanc J., Hurtado H. A. M., Molon G., Lee M. H., Mantas I., Mondillo S., Lee C. -H., Jattin F. M., Moniz P., Lehman J., Maqueda V., Mont L., Leitao A., Marchionni N., Montagud V., Lellouche N., Ortuno F. M., Montana O., Lelonek M., Santana A. M., Monti C., Lenarczyk R., Martinez J., Moretti L., Lenderink T., Maskova P., Mori K., Gonzalez S. L., Hernandez N. M., Moriarty A., Leong-Sit P., Matsuda K., Morka J., Leschke M., Maurer T., Moschini L., Ley N., Mauro C., Moschos N., Li Z., May E., Mugge A., Mayer N., Mulhearn T. J., Muresan C., Jose E. P., Precoma D. B., Muriago M., Padilla F. G. P., Prelle A., Musial W., Rios V. P., Prodafikas J., Musser C. W., Pajes G., Protasov K., Musumeci F., Pandey A. S., Pye M., Nageh T., Paparella G., Qiu Z., Nakagawa H., Paris F., Quedillac J. -M., Nakamura Y., Park H. W., Raev D., Nakayama T., Park J. S., Grado C. A. R., Nam G. -B., Parthenakis F., Rahimi S., Nanna M., Passamonti E., Raisaro A., Natarajan I., Patel R. J., Rama B., Nayak H. M., Patel J., Ramos R., Naydenov S., Patel M., Ranieri M., Nazlic J., Patrick J., Raposo N., Nechita A. C., Jimenez R. P., Rashba E., Nechvatal L., Paz A., Rauch-Kroehnert U., Negron S. A., Pengo V., Reddy R., Neiman J., Pentz W., Renda G., Neuenschwander F. C., Perez B., Reza S., Neves D., Rios A. M. P., Ria L., Neykova A., Perez-Cabezas A., Richter D., Miguel R. N., Perlman R., Rickli H., Nijmeh G., Persic V., Rieker W., Nizov A., Perticone F., Vera T. R., Campos R. N., Peters T. K., Ritt L. E., Nossan J., Petkar S., Roberts D., Novikova T., Pezo L. F., Briones I. R., Nowalany-Kozielska E., Pflucke C., Escudero A. E. R., Nsah E., Pham D. N., Pascual C. R., Fragoso J. C. N., Phillips R. T., Roman M., Nurgalieva S., Phlaum S., Romeo F., Nuyens D., Pieters D., Ronner E., Nyvad O., Pineau J., Roux J. -F., de Los Rios Ibarra M. O., Pinter A., Rozkova N., O'Donnell P., Pinto F., Rubacek M., O'Donnell M., Pisters R., Rubalcava F., Oh S., Pivac N., Russo A. M., Oh Y. S., Pocanic D., Rutgers M. P., Oh D., Podoleanu C., Rybak K., O'Hara G., Politano A., Said S., Oikonomou K., Poljakovic Z., Sakamoto T., Olivares C., Pollock S., Salacata A., Oliver R., Garcea J. P., Salem A., Ruiz R. O., Poppert H., Bodes R. S., Olympios C., Porcu M., Saltzman M. A., Omaszuk-Kazberuk A., Reino A. P., Salvioni A., Asensi J. O., Prasad N., Vallejo G. S., Fernandez M. S., Sokal A., Tu T. M., Saporito W. F., Yan Y. S. O., Tuininga Y., Sarikonda K., Sotolongo R., Turakhia M., Sasaoka T., de Souza O. F., Turk S., Sati H., Sparby J. A., Turner W., Savelieva I., Spinar J., Tveit A., Scala P. -J., Sprigings D., Tytus R., Schellinger P., Spyropoulos A. C., Valadao C., Scherr C., Stakos D., van Bergen P. F. M. M., Schmitz L., Steinwender C., van de Borne P., Schmitz K. -H., Stergiou G., van den Berg B. J., Schmitz B., Stiell I., van der Zwaan C., Schnabel T., Stoddard M., Van Eck M., Schnupp S., Stoikov A., Vanacker P., Schoeniger P., Streb W., Vasilev D., Schon N., Styliadis I., Vasilikos V., Schwimmbeck P., Su G., Vasilyev M., Seamark C., Su X., Veerareddy S., Searles G., Sudnik W., Mino M. V., Seidl K. -H., Sukles K., Venkataraman A., Seidman B., Sun X., Verdecchia P., Sek J., Swart H., Versaci F., Sekaran L., Szavits-Nossan J., Vester E. G., Serrati C., Taggeselle J., Vial H., Shah N., Takagi Y., Victory J., Shah V., Takhar A. P. S., Villamil A., Shah A., Tamm A., Vincent M., Shah S., Tanaka K., Vlastaris A., Sharma V. K., Tanawuttiwat T., Dahl J., Shaw L., Tang S., Vora K., Sheikh K. H., Tang A., Vranian R. B., Shimizu N., Tarsi G., Wakefield P., Shimomura H., Tassinari T., Wang N., Shin D. -G., Tayal A., Wang M., Shin E. -S., Tayebjee M., Wang X., Shite J., Berg J. M., Wang F., Sibilio G., Tesloianu D., Wang T., Silver F., The S. H. K., Warner A. L., Sime I., Thomas D., Watanabe K., Simmers T. A., Timsit S., Wei J., Singh N., Tobaru T., Weimar C., Siostrzonek P., Tomasik A. R., Weiner S., Smadja D., Torosoff M., Weinrich R., Smith D. W., Touze E., Wen M. -S., Snitman M., Trendafilova E., Wiemer M., Filho D. S., Tsai W. K., Wiggers P., Soda H., Tse H. F., Wilke A., Sofley C., Tsutsui H., Williams D., Williams M. L., Yan P. Y. B., Zhang P., Witzenbichler B., Yang T., Zhang J., Wong B., Yao J., Zhao S. P., Wong K. S. L., Yeh K. -H., Zhao Y., Wozakowska-Kaplon B., Yin W. H., Zhao Z., Wu S., Yotov Y., Zheng Y., Wu R. C., Zahn R., Zhou J., Wunderlich S., Zarich S., Zimmermann S., Wyatt N., Zenin S., Zini A., Wylie J., Zeuthen E. L., Zizzo S., Xu Y., Zhang H., Zong W., Xu X., Zhang D., Zukerman L. S., Yamanoue H., Zhang X., Yamashita T., Cardiology, ACS - Heart failure & arrhythmias, Lip G.Y.H., Kotalczyk A., Teutsch C., Diener H.-C., Dubner S.J., Halperin J.L., Ma C.-S., Rothman K.J., Marler S., Gurusamy V.K., Huisman M.V., Abban D.W., Aziz E., Kalan M.B., Abdul N., Backes L.M., Bradman D., Abud A.M., Badings E., Brautigam D., Adams F., Bagni E., Breton N., Addala S., Baker S.H., Brouwers P.J.A.M., Adragao P., Bala R., Browne K., Ageno W., Baldi A., Cortada J.B., Aggarwal R., Bando S., Bruni A., Agosti S., Banerjee S., Brunschwig C., Agostoni P., Bank A., Buathier H., Aguilar F., Esquivias G.B., Buhl A., Linares J.A., Barr C., Bullinga J., Aguinaga L., Bartlett M., Cabrera J.W., Ahmed J., Basic Kes V., Caccavo A., Aiello A., Baula G., Cai S., Ainsworth P., Behrens S., Caine S., Aiub J.R., Bell A., Calo L., Al-Dallow R., Benedetti R., Calvi V., Alderson L., Mazuecos J.B., Sanchez M.C., Velasco J.A.A., Benhalima B., Candeias R., Alexopoulos D., Bergler-Klein J., Capuano V., Manterola F.A., Berneau J.-B., Capucci A., Aliyar P., Bernstein R.A., Caputo R., Alonso D., Berrospi P., Rizo T.C., da Costa F.A.A., Berti S., Cardona F., Amado J., Berz A., da Costa Darrieux F.C., Amara W., Best E., Vera Y.C.D., Amelot M., Bettencourt P., Carolei A., Amjadi N., Betzu R., Carreno S., Ammirati F., Bhagwat R., Carvalho P., Andrade M., Bhatta L., Cary S., Andrawis N., Biscione F., Casu G., Annoni G., Bisignani G., Cavallini C., Ansalone G., Black T., Cayla G., Ariani M.K., Bloch M.J., Celentano A., Arias J.C., Bloom S., Cha T.-J., Armero S., Blumberg E., Cha K.S., Arora C., Bo M., Chae J.K., Aslam M.S., Bohmer E., Chalamidas K., Asselman M., Bollmann A., Challappa K., Audouin P., Bongiorni M.G., Chand S.P., Augenbraun C., Boriani G., Chandrashekar H., Aydin S., Boswijk D.J., Chartier L., Bott J., Chatterjee K., Ayryanova I., Bottacchi E., Ayala C.A.C., Cheema A., Davis G., Evonich R., Davy J.-M., Evseeva O., Chen L., Dayer M., Ezhov A., Chen S.-A., De Biasio M., Fahmy R., Chen J.H., De Bonis S., Fang Q., Chiang F.-T., De Caterina R., Farsad R., Chiarella F., De Franceschi T., Fauchier L., Chih-Chan L., de Groot J.R., Favale S., Cho Y.K., De Horta J., Fayard M., Choi J.-I., De La Briolle A., Fedele J.L., Choi D.J., de la Pena Topete G., Fedele F., Chouinard G., de Paola A.A.V., Fedorishina O., Chow D.H.-F., de Souza W., Fera S.R., Chrysos D., de Veer A., Ferreira L.G.G., Chumakova G., De Wolf L., Ferreira J., Valenzuela E.J.J.R.C., Decoulx E., Ferri C., Nica N.C., Deepak S., Ferrier A., Cislowski D.J., Defaye P., Ferro H., Clay A., Munoz F.D.-C., Finsen A., Clifford P., Brkljacic D.D., First B., Cohen A., Deumite N.J., Fischer S., Cohen M., Di Legge S., Fonseca C., Cohen S., Diemberger I., Almeida L.F., Colivicchi F., Dietz D., Forman S., Collins R., Dionisio P., Frandsen B., Colonna P., Dong Q., French W., Compton S., dos Santos F.R., Friedman K., Connolly D., Dotcheva E., Friese A., Conti A., Doukky R., Fruntelata A.G., Buenostro G.C., D'Souza A., Fujii S., Coodley G., Dubrey S., Fumagalli S., Cooper M., Ducrocq X., Fundamenski M., Coronel J., Dupljakov D., Furukawa Y., Corso G., Duque M., Gabelmann M., Sales J.C., Dutta D., Gabra N., Cottin Y., Duvilla N., Gadsboll N., Covalesky J., Duygun A., Galinier M., Cracan A., Dziewas R., Gammelgaard A., Crea F., Eaton C.B., Ganeshkumar P., Crean P., Eaves W., Gans C., Crenshaw J., Ebels-Tuinbeek L.A., Quintana A.G., Cullen T., Ehrlich C., Gartenlaub O., Darius H., Eichinger-Hasenauer S., Gaspardone A., Dary P., Eisenberg S.J., Genz C., Dascotte O., Jabali A.E., Georger F., Dauber I., Shahawy M.E., Georges J.-L., Davalos V., Hernandes M.E., Georgeson S., Davies R., Izal A.E., Giedrimas E., Gierba M., Haruna T., Jarmukli N., Ortega I.G., Hayek E., Jeanfreau R.J., Gillespie E., Healey J., Jenkins R.D., Giniger A., Hearne S., Sanchez C.J., Giudici M.C., Heffernan M., Jimenez J., Gkotsis A., Heggelund G., Jobe R., Glotzer T.V., Heijmeriks J.A., Joen-Jakobsen T., Gmehling J., Hemels M., Jones N., Gniot J., Hendriks I., Jorge J.C.M., Goethals P., Henein S., Jouve B., Goldbarg S., Her S.-H., Jung B.C., Goldberg R., Hermany P., Jung K.T., Goldmann B., Del Rio J.E.H., Jung W., Golitsyn S., Higashino Y., Kachkovskiy M., Gomez S., Hill M., Kafkala K., Mesa J.G., Hisadome T., Kalinina L., Gonzalez V.B., Hishida E., Kallmunzer B., Hermosillo J.A.G., Hoffer E., Kamali F., Lopez V.M.G., Hoghton M., Kamo T., Gorka H., Hong K., Kampus P., Gornick C., Hong S., Kashou H., Gorog D., Horbach S., Kastrup A., Gottipaty V., Horiuchi M., Katsivas A., Goube P., Hou Y., Kaufman E., Goudevenos I., Hsing J., Kawai K., Graham B., Huang C.-H., Kawajiri K., Greer G.S., Huckins D., Kazmierski J.F., Gremmler U., Hughes K., Keeling P., Grena P.G., Huizinga A., Saraiva J.F.K., Grond M., Hulsman E.L., Ketova G., Gronda E., Hung K.-C., Khaira A.S., Gronefeld G., Hwang G.-S., Khripun A., Gu X., Ikpoh M., Kim D.-I., Torres I.G.T., Imberti D., Kim Y.H., Guardigli G., Ince H., Kim N.H., Guevara C., Indolfi C., Kim D.K., Guignier A., Inoue S., Kim J.S., Gulizia M., Irles D., Gumbley M., Iseki H., Kim K.S., Gunther A., Israel C.N., Kim J., Ha A., Iteld B., Kinova E., Hahalis G., Iyer V., Klein A., Hakas J., Jackson-Voyzey E., Kmetzo J.J., Hall C., Jaffrani N., Kneller G.L., Han B., Jager F., Knezevic A., Han S., James M., Koh S.M.A., Hargrove J., Jang S.-W., Koide S., Hargroves D., Jaramillo N., Kollias A., Kooistra J.A., Li W., McClure J., Koons J., Li X., McCormack T., Koschutnik M., Lichy C., McGarity W., Kostis W.J., Lieber I., McIntyre H., Kovacic D., Rodriguez R.H.L., McLaurin B., Kowalczyk J., Lin H., Alvaro F., Palomino M., Koziolova N., Melandri F., Kraft P., Liu F., Meno H., Kragten J.A., Liu H., Menzies D., Krantz M., Esperon G.L., Mercader M., Krause L., Navarro N.L., Meyer C., Krenning B.J., Lo E., Meyer B.J., Krikke F., Lokshyn S., Miarka J., Kromhout Z., Lopez A., Mibach F., Krysiak W., Lopez-Sendon J.L., Michalski D., Kumar P., Filho A.M.L., Michel P., Kumler T., Lorraine R.S., Chreih R.M., Kuniss M., Luengas C.A., Luengas A., Mikdadi G., Kuo J.-Y., Luke R., Mikus M., Kuppers A., Luo M., Milicic D., Kurrelmeyer K., Lupovitch S., Militaru C., Kwak C.H., Lyrer P., Minaie S., Laboulle B., Ma C., Minescu B., Labovitz A., Ma G., Mintale I., Ter Lai W., Madariaga I., Mirault T., Lam A., Maeno K., Mirro M.J., Lam Y.Y., Magnin D., Mistry D., Lanas Zanetti F., Maid G., Miu N.V., Landau C., Mainigi S.K., Miyamoto N., Landini G., Makaritsis K., Moccetti T., Lanna Figueiredo E., Malhotra R., Mohammed A., Larsen T., Manning R., Nor A.M., Lavandier K., Manolis A., Mollerus M., LeBlanc J., Hurtado H.A.M., Molon G., Lee M.H., Mantas I., Mondillo S., Lee C.-H., Jattin F.M., Moniz P., Lehman J., Maqueda V., Mont L., Leitao A., Marchionni N., Montagud V., Lellouche N., Ortuno F.M., Montana O., Lelonek M., Santana A.M., Monti C., Lenarczyk R., Martinez J., Moretti L., Lenderink T., Maskova P., Mori K., Gonzalez S.L., Hernandez N.M., Moriarty A., Leong-Sit P., Matsuda K., Morka J., Leschke M., Maurer T., Moschini L., Ley N., Mauro C., Moschos N., Li Z., May E., Mugge A., Mayer N., Mulhearn T.J., Muresan C., Jose E.P., Precoma D.B., Muriago M., Padilla F.G.P., Prelle A., Musial W., Rios V.P., Prodafikas J., Musser C.W., Pajes G., Protasov K., Musumeci F., Pandey A.S., Pye M., Nageh T., Paparella G., Qiu Z., Nakagawa H., Paris F., Quedillac J.-M., Nakamura Y., Park H.W., Raev D., Nakayama T., Park J.S., Grado C.A.R., Nam G.-B., Parthenakis F., Rahimi S., Nanna M., Passamonti E., Raisaro A., Natarajan I., Patel R.J., Rama B., Nayak H.M., Patel J., Ramos R., Naydenov S., Patel M., Ranieri M., Nazlic J., Patrick J., Raposo N., Nechita A.C., Jimenez R.P., Rashba E., Nechvatal L., Paz A., Rauch-Kroehnert U., Negron S.A., Pengo V., Reddy R., Neiman J., Pentz W., Renda G., Neuenschwander F.C., Perez B., Reza S., Neves D., Rios A.M.P., Ria L., Neykova A., Perez-Cabezas A., Richter D., Miguel R.N., Perlman R., Rickli H., Nijmeh G., Persic V., Rieker W., Nizov A., Perticone F., Vera T.R., Campos R.N., Peters T.K., Ritt L.E., Nossan J., Petkar S., Roberts D., Novikova T., Pezo L.F., Briones I.R., Nowalany-Kozielska E., Pflucke C., Escudero A.E.R., Nsah E., Pham D.N., Pascual C.R., Fragoso J.C.N., Phillips R.T., Roman M., Nurgalieva S., Phlaum S., Romeo F., Nuyens D., Pieters D., Ronner E., Nyvad O., Pineau J., Roux J.-F., de Los Rios Ibarra M.O., Pinter A., Rozkova N., O'Donnell P., Pinto F., Rubacek M., O'Donnell M., Pisters R., Rubalcava F., Oh S., Pivac N., Russo A.M., Oh Y.S., Pocanic D., Rutgers M.P., Oh D., Podoleanu C., Rybak K., O'Hara G., Politano A., Said S., Oikonomou K., Poljakovic Z., Sakamoto T., Olivares C., Pollock S., Salacata A., Oliver R., Garcea J.P., Salem A., Ruiz R.O., Poppert H., Bodes R.S., Olympios C., Porcu M., Saltzman M.A., Omaszuk-Kazberuk A., Reino A.P., Salvioni A., Asensi J.O., Prasad N., Vallejo G.S., Fernandez M.S., Sokal A., Tu T.M., Saporito W.F., Yan Y.S.O., Tuininga Y., Sarikonda K., Sotolongo R., Turakhia M., Sasaoka T., de Souza O.F., Turk S., Sati H., Sparby J.A., Turner W., Savelieva I., Spinar J., Tveit A., Scala P.-J., Sprigings D., Tytus R., Schellinger P., Spyropoulos A.C., Valadao C., Scherr C., Stakos D., van Bergen P.F.M.M., Schmitz L., Steinwender C., van de Borne P., Schmitz K.-H., Stergiou G., van den Berg B.J., Schmitz B., Stiell I., van der Zwaan C., Schnabel T., Stoddard M., Van Eck M., Schnupp S., Stoikov A., Vanacker P., Schoeniger P., Streb W., Vasilev D., Schon N., Styliadis I., Vasilikos V., Schwimmbeck P., Su G., Vasilyev M., Seamark C., Su X., Veerareddy S., Searles G., Sudnik W., Mino M.V., Seidl K.-H., Sukles K., Venkataraman A., Seidman B., Sun X., Verdecchia P., Sek J., Swart H., Versaci F., Sekaran L., Szavits-Nossan J., Vester E.G., Serrati C., Taggeselle J., Vial H., Shah N., Takagi Y., Victory J., Shah V., Takhar A.P.S., Villamil A., Shah A., Tamm A., Vincent M., Shah S., Tanaka K., Vlastaris A., Sharma V.K., Tanawuttiwat T., Dahl J., Shaw L., Tang S., Vora K., Sheikh K.H., Tang A., Vranian R.B., Shimizu N., Tarsi G., Wakefield P., Shimomura H., Tassinari T., Wang N., Shin D.-G., Tayal A., Wang M., Shin E.-S., Tayebjee M., Wang X., Shite J., Berg J.M., Wang F., Sibilio G., Tesloianu D., Wang T., Silver F., The S.H.K., Warner A.L., Sime I., Thomas D., Watanabe K., Simmers T.A., Timsit S., Wei J., Singh N., Tobaru T., Weimar C., Siostrzonek P., Tomasik A.R., Weiner S., Smadja D., Torosoff M., Weinrich R., Smith D.W., Touze E., Wen M.-S., Snitman M., Trendafilova E., Wiemer M., Filho D.S., Tsai W.K., Wiggers P., Soda H., Tse H.F., Wilke A., Sofley C., Tsutsui H., Williams D., Williams M.L., Yan P.Y.B., Zhang P., Witzenbichler B., Yang T., Zhang J., Wong B., Yao J., Zhao S.P., Wong K.S.L., Yeh K.-H., Zhao Y., Wozakowska-Kaplon B., Yin W.H., Zhao Z., Wu S., Yotov Y., Zheng Y., Wu R.C., Zahn R., Zhou J., Wunderlich S., Zarich S., Zimmermann S., Wyatt N., Zenin S., Zini A., Wylie J., Zeuthen E.L., Zizzo S., Xu Y., Zhang H., Zong W., Xu X., Zhang D., Zukerman L.S., Yamanoue H., Zhang X., and Yamashita T.
- Subjects
Apixaban ,Atrial fibrillation ,Dabigatran ,Non-vitamin K antagonists ,Rivaroxaban ,Pyridones ,Medizin ,Myocardial Infarction ,Administration, Oral ,Anticoagulants ,Hemorrhage ,General Medicine ,Non-vitamin K antagonist ,Stroke ,Clinical Trials, Phase III as Topic ,Humans ,Prospective Studies ,Registries ,Cardiology and Cardiovascular Medicine - Abstract
Background and purpose Prospectively collected data comparing the safety and effectiveness of individual non-vitamin K antagonists (NOACs) are lacking. Our objective was to directly compare the effectiveness and safety of NOACs in patients with newly diagnosed atrial fibrillation (AF). Methods In GLORIA-AF, a large, prospective, global registry program, consecutive patients with newly diagnosed AF were followed for 3 years. The comparative analyses for (1) dabigatran vs rivaroxaban or apixaban and (2) rivaroxaban vs apixaban were performed on propensity score (PS)-matched patient sets. Proportional hazards regression was used to estimate hazard ratios (HRs) for outcomes of interest. Results The GLORIA-AF Phase III registry enrolled 21,300 patients between January 2014 and December 2016. Of these, 3839 were prescribed dabigatran, 4015 rivaroxaban and 4505 apixaban, with median ages of 71.0, 71.0, and 73.0 years, respectively. In the PS-matched set, the adjusted HRs and 95% confidence intervals (CIs) for dabigatran vs rivaroxaban were, for stroke: 1.27 (0.79–2.03), major bleeding 0.59 (0.40–0.88), myocardial infarction 0.68 (0.40–1.16), and all-cause death 0.86 (0.67–1.10). For the comparison of dabigatran vs apixaban, in the PS-matched set, the adjusted HRs were, for stroke 1.16 (0.76–1.78), myocardial infarction 0.84 (0.48–1.46), major bleeding 0.98 (0.63–1.52) and all-cause death 1.01 (0.79–1.29). For the comparison of rivaroxaban vs apixaban, in the PS-matched set, the adjusted HRs were, for stroke 0.78 (0.52–1.19), myocardial infarction 0.96 (0.63–1.45), major bleeding 1.54 (1.14–2.08), and all-cause death 0.97 (0.80–1.19). Conclusions Patients treated with dabigatran had a 41% lower risk of major bleeding compared with rivaroxaban, but similar risks of stroke, MI, and death. Relative to apixaban, patients treated with dabigatran had similar risks of stroke, major bleeding, MI, and death. Rivaroxaban relative to apixaban had increased risk for major bleeding, but similar risks for stroke, MI, and death. Registration URL: https://www.clinicaltrials.gov. Unique identifiers: NCT01468701, NCT01671007. Date of registration: September 2013. Graphical abstract
- Published
- 2022
19. Role of continuous glucose monitoring in diabetic patients at high cardiovascular risk: an expert-based multidisciplinary Delphi consensus
- Author
-
Di Mario, Clara, Genovese, S., Lanza, Gaetano Antonio, Mannucci, E., Marenzi, Giancarlo, Sciatti, E., Pitocco, Dario, Avogaro, A., Bertuzzi, Paolo Francesco, Bonora, E., Borghi, Claudio, Buzzetti, R., Carugo, S., Capodanno, D., Consoli, A., Conti, A., Danesi, R., Bartolo, P., Ferrari, G. M. D., Favale, S., Giorda, C., Giorgino, F., Girelli, Alberto, Golino, P., Grigioni, F., Indolfi, C., Irace, C., Lovati, E., Maffettone, A., Masulli, M., Oliva, F. G., Oltrona Visconti, L., Orsi, Cosma Emilio, Pagotto, U., Paloscia, L., Parati, G., Perrone, Pia Alba Gloria, Piccirillo, G., Pozzilli, P., Pugliese, Giuseppe, Purrello, F., Ribichini, F., Rubboli, A., Senni, M., Trevisan, R., Tubili, C., Uguccioni, M., Di Mario, C, Genovese, S, Lanza, G, Mannucci, E, Marenzi, G, Sciatti, E, Pitocco, D, Avogaro, A, Bertuzzi, F, Bonora, E, Borghi, C, Buzzetti, R, Carugo, S, Capodanno, D, Consoli, A, Conti, A, Danesi, R, Bartolo, P, Ferrari, G, Favale, S, Giorda, C, Giorgino, F, Girelli, A, Golino, P, Grigioni, F, Indolfi, C, Irace, C, Lovati, E, Maffettone, A, Masulli, M, Oliva, F, Oltrona Visconti, L, Orsi, E, Pagotto, U, Paloscia, L, Parati, G, Perrone, P, Piccirillo, G, Pozzilli, P, Pugliese, G, Purrello, F, Ribichini, F, Rubboli, A, Senni, M, Trevisan, R, Tubili, C, and Uguccioni, M
- Subjects
Blood Glucose ,Consensus ,Delphi Technique ,Heart Diseases ,cardiovascular outcome ,continuous glucose monitoring ,delphi method ,glucometrics ,glycaemic variability ,time in range ,Endocrinology, Diabetes and Metabolism ,Blood Glucose Self-Monitoring ,Delphi method ,Settore MED/13 - ENDOCRINOLOGIA ,Cardiovascular outcome ,Glycaemic variability ,Hypoglycemia ,Diabetes Mellitus, Type 1 ,Diabetes Mellitus, Type 2 ,Cardiovascular Diseases ,Heart Disease Risk Factors ,Risk Factors ,Time in range ,Glucometric ,Humans ,Cardiology and Cardiovascular Medicine ,Continuous glucose monitoring - Abstract
Background Continuous glucose monitoring (CGM) shows in more detail the glycaemic pattern of diabetic subjects and provides several new parameters (“glucometrics”) to assess patients’ glycaemia and consensually guide treatment. A better control of glucose levels might result in improvement of clinical outcome and reduce disease complications. This study aimed to gather an expert consensus on the clinical and prognostic use of CGM in diabetic patients at high cardiovascular risk or with heart disease. Methods A list of 22 statements concerning type of patients who can benefit from CGM, prognostic impact of CGM in diabetic patients with heart disease, CGM use during acute cardiovascular events and educational issues of CGM were developed. Using a two-round Delphi methodology, the survey was distributed online to 42 Italian experts (21 diabetologists and 21 cardiologists) who rated their level of agreement with each statement on a 5-point Likert scale. Consensus was predefined as more than 66% of the panel agreeing/disagreeing with any given statement. Results Forty experts (95%) answered the survey. Every statement achieved a positive consensus. In particular, the panel expressed the feeling that CGM can be prognostically relevant for every diabetic patient (70%) and that is clinically useful also in the management of those with type 2 diabetes not treated with insulin (87.5%). The assessment of time in range (TIR), glycaemic variability (GV) and hypoglycaemic/hyperglycaemic episodes were considered relevant in the management of diabetic patients with heart disease (92.5% for TIR, 95% for GV, 97.5% for time spent in hypoglycaemia) and can improve the prognosis of those with ischaemic heart disease (100% for hypoglycaemia, 90% for hyperglycaemia) or with heart failure (87.5% for hypoglycaemia, 85% for TIR, 87.5% for GV). The experts retained that CGM can be used and can impact the short- and long-term prognosis during an acute cardiovascular event. Lastly, CGM has a recognized educational role for diabetic subjects. Conclusions According to this Delphi consensus, the clinical and prognostic use of CGM in diabetic patients at high cardiovascular risk is promising and deserves dedicated studies to confirm the experts’ feelings.
- Published
- 2022
20. Influence of obesity and overweight on the association between sleep-disordered breathing and atrial fibrillation: the DASAP-HF study
- Author
-
Boriani, G, primary, Diemberger, I, additional, Pisano', E C L, additional, Pieragnoli, P, additional, Locatelli, A, additional, Capucci, A, additional, Talarico, A, additional, Zecchin, M, additional, Rapacciuolo, A, additional, Piacenti, M, additional, Indolfi, C, additional, Arias, M A, additional, Checchinato, C, additional, and D'Onofrio, A, additional
- Published
- 2022
- Full Text
- View/download PDF
21. PCSK9 inhibitors: effectiveness of treatment and changes in background lipid-lowering therapy in a real world Italian population. The AT-TARGET-IT study
- Author
-
Perrone-Filardi, P, primary, Basile, C, additional, Asile, G, additional, Abbate, C, additional, Catalano, A, additional, Merlini, P A, additional, Calabro', P, additional, Iannuzzo, G, additional, Ciccone, M M, additional, Paloscia, L, additional, Varbella, F, additional, Brunetti, N D, additional, Indolfi, C, additional, Paolillo, S, additional, and Gargiulo, P, additional
- Published
- 2022
- Full Text
- View/download PDF
22. Italian Society of Cardiology (SIC) Expert consensus document: Post-acute cardiovascular sequelae of SARS-CoV-2 infection
- Author
-
Indolfi C., Barilla F., Basso C., Ciccone M. M., Curcio A., Gargiulo P., Nodari S., Mercuro G., Mancone M., Muscoli S., Pedrinelli R., Porcari A., Spaccarotella C., Romeo F., Sinagra G., Filardi P. P., Indolfi, C., Barilla, F., Basso, C., Ciccone, M. M., Curcio, A., Gargiulo, P., Nodari, S., Mercuro, G., Mancone, M., Muscoli, S., Pedrinelli, R., Porcari, A., Spaccarotella, C., Romeo, F., Sinagra, G., and Filardi, P. P.
- Abstract
Although the clinical course of COVID-19 in its acute phase is now delineated, less known is its late phase characterized by a heterogeneous series of sequelae affecting various organs and systems, including the cardiovascular system, which continue after the acute episode or arise after their resolution. This syndrome, now referred with the new acronym "PASC" (post-acute sequelae of SARS-CoV-2 infection) has been formally recognized by various scientific societies and international organizations that have proposed various definitions. The World Health Organization defines PASC, distinguishing it from "ongoing symptomatic COVID-19", as a condition that arises few weeks after infection, persists at least 8 weeks, and cannot be explained by alternative diagnoses.There are multiple mechanisms responsible for PASC: inflammation, immune activation, viral persistence, activation of latent viruses, endothelial dysfunction, impaired response to exercise, and profound cardiac deconditioning following viral infection. The key symptoms of PASC are palpitations, effort dyspnea, chest pain, exercise intolerance, and postural orthostatic tachycardia syndrome.For PASC treatment, it may be useful to take salt and fluid loading, to reduce symptoms such as tachycardia, palpitations, and/or orthostatic hypotension, or in some subjects the use of drugs such as beta-blockers, non-dihydropyridine calcium channel blockers, ivabradine, and fludrocortisone.Finally, in PASC a gradual resumption of physical activity is recommended, starting with recumbent or semi-recumbent exercise, such as cycling, swimming, or rowing, and then moving on to exercise in an upright position such as running when the ability to stand improves without dyspnea appearance. Exercise duration should also be short initially (5 to 10 min per day), with gradual increases as functional capacity improves.
- Published
- 2022
23. [Italian Society of Cardiology-Italian Society of Nephrology Consensus document: The cardio-renal interaction in the prevention and treatment of cardiovascular diseases - Part II: From preventive strategies to treatment of patients with cardio-renal damage]
- Author
-
Indolfi C., Barilla F., Basile C., Basso C., Cantaluppi V., Capasso G., Ciccone M. M., Contessi S., Curcio A., De Nicola L., Esposito C., Imeraj A., Lecis D., Mancone M., Marengo M., Mercuro G., Merlo M., Metra M., Adamo M., Muscoli S., Nodari S., Pagura L., Paoletti E., Paolillo S., Pedrinelli R., Filardi P. P., Pertosa G. B., Pezzato A., Pontremoli R., Romeo F., Ruggenenti P., Ronco C., Santoro A., Sinagra G., Spaccarotella C., Zippo D., Zoccali C., Messa P., Indolfi, C., Barilla, F., Basile, C., Basso, C., Cantaluppi, V., Capasso, G., Ciccone, M. M., Contessi, S., Curcio, A., De Nicola, L., Esposito, C., Imeraj, A., Lecis, D., Mancone, M., Marengo, M., Mercuro, G., Merlo, M., Metra, M., Adamo, M., Muscoli, S., Nodari, S., Pagura, L., Paoletti, E., Paolillo, S., Pedrinelli, R., Filardi, P. P., Pertosa, G. B., Pezzato, A., Pontremoli, R., Romeo, F., Ruggenenti, P., Ronco, C., Santoro, A., Sinagra, G., Spaccarotella, C., Zippo, D., Zoccali, C., and Messa, P.
- Subjects
Diabetes mellitu ,Consensus ,Cardiology ,Contrast Media ,Cardiovascular disease ,Atrial fibrillation ,Cardiovascular Diseases ,Nephrology ,Acute kidney disease ,Chronic kidney disease ,Humans ,Renal Insufficiency, Chronic ,Renal Insufficiency ,Hyperkaliemia ,Chronic - Abstract
Chronic kidney disease and cardiovascular disease are strictly connected each other with a bidirectional interaction. Thus, the prevention of cardio-renal damage, as its appropriate treatment, are essential steps for a correct management of long-term patients' prognosis. Several preventive and therapeutic strategies, pharmacological and not, are now available for cardio-renal damage prevention and treatment, and for the management of its complications. The second part of this consensus document focuses on the management and treatment of cardio-renal damage, directing the attention on the correct use of drugs that may slow renal disease progression, on the application of preventive strategies in case of invasive cardiac procedures with the use of contrast agents, and on the accurate use of cardiological drugs in patients with chronic kidney disease.
- Published
- 2022
24. Position paper of the Italian Society of Cardiology: The renin-angiotensin-aldosterone system (RAAS) blockade in heart failure patients - Part I: From RAAS identification to clinical trials
- Author
-
Filardi P. P., Paolillo S., Indolfi C., Agostoni P., Basso C., Barilla F., Correale M., Curcio A., Mancone M., Merlo M., Metra M., Muscoli S., Nodari S., Palazzuoli A., Pedrinelli R., Pontremoli R., Senni M., Volpe M., Sinagra G., Filardi, P. P., Paolillo, S., Indolfi, C., Agostoni, P., Basso, C., Barilla, F., Correale, M., Curcio, A., Mancone, M., Merlo, M., Metra, M., Muscoli, S., Nodari, S., Palazzuoli, A., Pedrinelli, R., Pontremoli, R., Senni, M., Volpe, M., and Sinagra, G.
- Subjects
Renin-Angiotensin System ,Heart Failure ,Clinical Trials as Topic ,Aminobutyrate ,Angiotensin Receptor Antagonist ,Biphenyl Compound ,Cardiology ,Tetrazole ,Human - Abstract
Renin-angiotensin-aldosterone (RAAS) system inhibition is a mainstay of the pharmacological treatment of heart failure with reduced ejection fraction and has been implemented by the introduction of angiotensin receptor-neprilysin inhibitors (ARNI), that combine RAAS inhibition with the inhibition of neprilysin, enhancing the favorable effects of natriuretic peptides. The PARADIGM-HF trial demonstrated a favorable effect of sacubitril/valsartan over enalapril in terms of mortality and heart failure hospitalization rate reduction. Then several randomized clinical trials and observational studies confirmed the favorable role of ARNI in different clinical scenarios, supporting the guideline class I recommendation for the use of sacubitril/valsartan in patients with reduced systolic function. The first part of this position paper summarizes the history of RAAS inhibition and reports the results of ARNI trials that support the recommendations of the most recent guidelines.
- Published
- 2022
25. From statin revolution to gene silencing therapy: 50 years of evolution in the treatment of hypercholesterolemia
- Author
-
Calabro P., De Ferrari G. M., Romeo F., Indolfi C., Filardi P. P., Calabro, P., De Ferrari, G. M., Romeo, F., Indolfi, C., and Filardi, P. P.
- Abstract
The last 50 years have experienced a rapid evolution in the development of lipid-lowering agents to reduce low-density lipoprotein cholesterol levels. This significant advance in medicine has not occurred without debate. Whether lowering blood cholesterol levels was beneficial has remained one of the most controversial issues during the past 50 years. The discovery of statins was the revolution that made it possible to delay and stop the progression of the atherosclerotic process resulting in improved health and longevity for millions of people. To date, statins remain the drugs of choice for the treatment of hypercholesterolemia. Despite their use, the risk of cardiovascular events persists. Therefore, the use of non-statin drugs, such as ezetimibe or PCSK9 inhibitors, in combination with statins has been shown to further reduce the risk of cardiovascular events. This review aims to summarize the advances in the field of lipid-lowering therapies over the past 50 years, focusing on advances in the development of drug therapies up to and including gene silencing or gene editing treatments that are expected in the near future.
- Published
- 2022
26. Position paper of the Italian Society of Cardiology: The renin-angiotensin-aldosterone system blockade in heart failure patients - Part II: Mechanistic effects of sacubitril/valsartan, placement in current guidelines and use in clinical practice
- Author
-
Filardi P. P., Indolfi C., Paolillo S., Agostoni P., Basso C., Barilla F., Correale M., Curcio A., Mancone M., Merlo M., Metra M., Muscoli S., Nodari S., Palazzuoli A., Pedrinelli R., Pontremoli R., Senni M., Volpe M., Sinagra G., Filardi, P. P., Indolfi, C., Paolillo, S., Agostoni, P., Basso, C., Barilla, F., Correale, M., Curcio, A., Mancone, M., Merlo, M., Metra, M., Muscoli, S., Nodari, S., Palazzuoli, A., Pedrinelli, R., Pontremoli, R., Senni, M., Volpe, M., and Sinagra, G.
- Subjects
Renin-Angiotensin System ,Heart Failure ,Aminobutyrate ,Angiotensin Receptor Antagonist ,Biphenyl Compound ,Cardiology ,Valsartan ,Tetrazole ,Human - Abstract
The use of sacubitril/valsartan has been fully recognized in the most recent European and American guidelines that recommend in class I the prescription of this drug in heart failure patients with reduced systolic function. Besides the effects on cardiovascular mortality and heart failure hospitalization, sacubitril/valsartan significantly reduces NT-proBNP levels and improves cardiac remodeling, recognized as one of the mechanistic effects of the drug that is linked to favorable prognostic effects. A careful evaluation of the patients' clinical profile is needed to implement the use of sacubitril/valsartan into clinical practice and to make the treatment successful. This second part of the position paper focuses on the mechanistic effects of angiotensin receptor-neprilysin inhibitors and on its placement in current guidelines, also suggesting the use of sacubitril/valsartan in specific clinical settings.
- Published
- 2022
27. Position paper of the Italian Society of Cardiology: The renin-angiotensin-aldosterone system (RAAS) blockade in heart failure patients - Part I: From RAAS identification to clinical trials [Position paper della Società Italiana di Cardiologia: Il blocco del sistema renina-angiotensina-aldosterone (RAAS) nel paziente con scompenso cardiaco – Parte I: Dalla scoperta del RAAS ai trial clinici]
- Author
-
Filardi P. P., Paolillo S., Indolfi C., Agostoni P., Basso C., Barilla F., Correale M., Curcio A., Mancone M., Merlo M., Metra M., Muscoli S., Nodari S., Palazzuoli A., Pedrinelli R., Pontremoli R., Senni M., Volpe M., Sinagra G., Filardi, P, Paolillo, S, Indolfi, C, Agostoni, P, Basso, C, Barilla, F, Correale, M, Curcio, A, Mancone, M, Merlo, M, Metra, M, Muscoli, S, Nodari, S, Palazzuoli, A, Pedrinelli, R, Pontremoli, R, Senni, M, Volpe, M, and Sinagra, G
- Subjects
Heart Failure ,Renin-Angiotensin System ,Aminobutyrate ,Angiotensin Receptor Antagonist ,Scompenso cardiaco ,Biphenyl Compound ,Cardiology ,Inibitori del recettore dell’angiotensina e della neprilisina ,Sacubitril/valsartan ,Scompenso cardiaco a frazione di eiezione ridotta ,Linee guida ,Tetrazole ,Human - Abstract
L’inibizione del sistema renina-angiotensina-aldosterone (RAAS) rappresenta un caposaldo del trattamento farmacologico dello scompenso cardiaco a ridotta frazione di eiezione ed è stato potenziato dall’arrivo degli inibitori del recettore dell’angiotensina e della neprilisina (ARNI) che combinano l’inibizione del RAAS con l’inibizione della neprilisina responsabile di un incremento delle attività favorevoli dei peptidi natriuretici. Sacubitril/valsartan ha dimostrato nello studio PARADIGM-HF un netto vantaggio rispetto ad enalapril in termini di riduzione di mortalità ed ospedalizzazioni per insufficienza cardiaca e numerosi altri trial randomizzati e studi clinici ne hanno testato l’efficacia in differenti contesti. Dai risultati di questi studi è derivata la raccomandazione di classe I per l’utilizzo del farmaco in pazienti con frazione di eiezione ridotta. La prima parte di questo position paper esplora la storia dell’inibizione del RAAS per passare poi ad una dettagliata analisi dei risultati ottenuti negli studi clinici con gli ARNI che ne supportano le raccomandazioni delle più recenti linee guida. Renin-angiotensin-aldosterone (RAAS) system inhibition is a mainstay of the pharmacological treatment of heart failure with reduced ejection fraction and has been implemented by the introduction of angiotensin receptor-neprilysin inhibitors (ARNI), that combine RAAS inhibition with the inhibition of neprilysin, enhancing the favorable effects of natriuretic peptides. The PARADIGM-HF trial demonstrated a favorable effect of sacubitril/valsartan over enalapril in terms of mortality and heart failure hospitalization rate reduction. Then several randomized clinical trials and observational studies confirmed the favorable role of ARNI in different clinical scenarios, supporting the guideline class I recommendation for the use of sacubitrilvalsartan in patients with reduced systolic function. The first part of this position paper summarizes the history of RAAS inhibition and reports the results of ARNI trials that support the recommendations of the most recent guidelines.
- Published
- 2022
28. The role of mitochondrial dynamics in cardiovascular diseases
- Author
-
Forte, M, Schirone, L, Ameri, P, Basso, C, Catalucci, D, Modica, J, Chimenti, C, Crotti, L, Frati, G, Rubattu, S, Schiattarella, G, Torella, D, Perrino, C, Indolfi, C, Sciarretta, S, Forte M, Schirone L, Ameri P, Basso C, Catalucci D, Modica J, Chimenti C, Crotti L, Frati G, Rubattu S, Schiattarella GG, Torella D, Perrino C, Indolfi C, Sciarretta S, Forte, M, Schirone, L, Ameri, P, Basso, C, Catalucci, D, Modica, J, Chimenti, C, Crotti, L, Frati, G, Rubattu, S, Schiattarella, G, Torella, D, Perrino, C, Indolfi, C, Sciarretta, S, Forte M, Schirone L, Ameri P, Basso C, Catalucci D, Modica J, Chimenti C, Crotti L, Frati G, Rubattu S, Schiattarella GG, Torella D, Perrino C, Indolfi C, and Sciarretta S
- Abstract
The process of mitochondrial dynamics is emerging as a core player in cardiovascular homeostasis. This process refers to the co-ordinated cycles of biogenesis, fusion, fission and degradation to which mitochondria constantly undergo to maintain their integrity, distribution and size. These mechanisms represent an early response to mitochondrial stress, confining organelle portions that are irreversibly damaged and preserving mitochondrial function. Accumulating evidence demonstrates that impairment in mitochondrial dynamics leads to myocardial damage and cardiac disease progression in a variety of disease models, including pressure overload, ischaemia/reperfusion and metabolic disturbance. These findings suggest that modulation of mitochondrial dynamics may be considered as a valid therapeutic strategy in cardiovascular diseases. In this review, we discuss the current evidence about the role of mitochondrial dynamics in cardiac pathophysiology, with a particular focus on the mechanisms underlying the development of cardiac hypertrophy and heart failure, metabolic and genetic cardiomyopathies, ischaemia/reperfusion injury, atherosclerosis and ischaemic stroke.
- Published
- 2021
29. Novel basic science insights to improve the management of heart failure: Review of the working group on cellular and molecular biology of the heart of the italian society of cardiology
- Author
-
Ameri, P, Schiattarella, G, Crotti, L, Torchio, M, Bertero, E, Rodolico, D, Forte, M, Di Mauro, V, Paolillo, R, Chimenti, C, Torella, D, Catalucci, D, Sciarretta, S, Basso, C, Indolfi, C, Perrino, C, Ameri P, Schiattarella GG, Crotti L, Torchio M, Bertero E, Rodolico D, Forte M, Di Mauro V, Paolillo R, Chimenti C, Torella D, Catalucci D, Sciarretta S, Basso C, Indolfi C, Perrino C., Ameri, P, Schiattarella, G, Crotti, L, Torchio, M, Bertero, E, Rodolico, D, Forte, M, Di Mauro, V, Paolillo, R, Chimenti, C, Torella, D, Catalucci, D, Sciarretta, S, Basso, C, Indolfi, C, Perrino, C, Ameri P, Schiattarella GG, Crotti L, Torchio M, Bertero E, Rodolico D, Forte M, Di Mauro V, Paolillo R, Chimenti C, Torella D, Catalucci D, Sciarretta S, Basso C, Indolfi C, and Perrino C.
- Abstract
Despite important advances in diagnosis and treatment, heart failure (HF) remains a syndrome with substantial morbidity and dismal prognosis. Although implementation and optimization of existing technologies and drugs may lead to better management of HF, new or alternative strategies are desirable. In this regard, basic science is expected to give fundamental inputs, by expanding the knowledge of the pathways underlying HF development and progression, identifying approaches that may improve HF detection and prognostic stratification, and finding novel treatments. Here, we discuss recent basic science insights that encompass major areas of translational research in HF and have high potential clinical impact.
- Published
- 2020
30. Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era
- Author
-
De Rosa, S, Spaccarotella, C, Basso, C, Calabro, M, Curcio, A, Filardi, P, Mancone, M, Mercuro, G, Muscoli, S, Nodari, S, Pedrinelli, R, Sinagra, G, Indolfi, C, Angelini, F, Barilla, F, Bartorelli, A, Benedetto, F, Bernabo, P, Bolognese, L, Briani, M, Cacciavillani, L, Calabrese, A, Calabro, P, Caliendo, L, Calo, L, Casella, G, Casu, G, Cavallini, C, Ciampi, Q, Ciccone, M, Comito, M, Corrada, E, Crea, F, D'Andrea, A, D'Urbano, M, De Caterina, R, De Ferrari, G, De Ponti, R, Della Mattia, A, DI Mario, C, Donnazzan, L, Esposito, G, Fedele, F, Ferraro, A, Galasso, G, Galie, N, Gnecchi, M, Golino, P, Golia, B, Guarini, P, Leonardi, S, Locuratolo, N, Luzza, F, Manganiello, V, Francesca Marchetti, M, Marenzi, G, Margonato, A, Meloni, L, Metra, M, Milo, M, Mongiardo, A, Monzo, L, Morisco, C, Novo, G, Pancaldi, S, Parollo, M, Paterno, G, Patti, G, Priori, S, Ravera, A, Giuseppe Rebuzzi, A, Rossi, M, Scherillo, M, Semprini, F, Senni, M, Sibilio, G, Siviglia, M, Tamburino, C, Tortorici, G, Versace, F, Villari, B, Volpe, M, De Rosa S., Spaccarotella C., Basso C., Calabro M. P., Curcio A., Filardi P. P., Mancone M., Mercuro G., Muscoli S., Nodari S., Pedrinelli R., Sinagra G., Indolfi C., Angelini F., Barilla F., Bartorelli A., Benedetto F., Bernabo P., Bolognese L., Briani M., Cacciavillani L., Calabrese A., Calabro P., Caliendo L., Calo L., Casella G., Casu G., Cavallini C., Ciampi Q., Ciccone M., Comito M., Corrada E., Crea F., D'Andrea A., D'Urbano M., De Caterina R., De Ferrari G., De Ponti R., Della Mattia A., DI Mario C., Donnazzan L., Esposito G., Fedele F., Ferraro A., Galasso G., Galie N., Gnecchi M., Golino P., Golia B., Guarini P., Leonardi S., Locuratolo N., Luzza F., Manganiello V., Francesca Marchetti M., Marenzi G., Margonato A., Meloni L., Metra M., Milo M., Mongiardo A., Monzo L., Morisco C., Novo G., Pancaldi S., Parollo M., Paterno G., Patti G., Priori S., Ravera A., Giuseppe Rebuzzi A., Rossi M., Scherillo M., Semprini F., Senni M., Sibilio G., Siviglia M., Tamburino C., Tortorici G., Versace F., Villari B., Volpe M., De Rosa, S, Spaccarotella, C, Basso, C, Calabro, M, Curcio, A, Filardi, P, Mancone, M, Mercuro, G, Muscoli, S, Nodari, S, Pedrinelli, R, Sinagra, G, Indolfi, C, Angelini, F, Barilla, F, Bartorelli, A, Benedetto, F, Bernabo, P, Bolognese, L, Briani, M, Cacciavillani, L, Calabrese, A, Calabro, P, Caliendo, L, Calo, L, Casella, G, Casu, G, Cavallini, C, Ciampi, Q, Ciccone, M, Comito, M, Corrada, E, Crea, F, D'Andrea, A, D'Urbano, M, De Caterina, R, De Ferrari, G, De Ponti, R, Della Mattia, A, DI Mario, C, Donnazzan, L, Esposito, G, Fedele, F, Ferraro, A, Galasso, G, Galie, N, Gnecchi, M, Golino, P, Golia, B, Guarini, P, Leonardi, S, Locuratolo, N, Luzza, F, Manganiello, V, Francesca Marchetti, M, Marenzi, G, Margonato, A, Meloni, L, Metra, M, Milo, M, Mongiardo, A, Monzo, L, Morisco, C, Novo, G, Pancaldi, S, Parollo, M, Paterno, G, Patti, G, Priori, S, Ravera, A, Giuseppe Rebuzzi, A, Rossi, M, Scherillo, M, Semprini, F, Senni, M, Sibilio, G, Siviglia, M, Tamburino, C, Tortorici, G, Versace, F, Villari, B, Volpe, M, De Rosa S., Spaccarotella C., Basso C., Calabro M. P., Curcio A., Filardi P. P., Mancone M., Mercuro G., Muscoli S., Nodari S., Pedrinelli R., Sinagra G., Indolfi C., Angelini F., Barilla F., Bartorelli A., Benedetto F., Bernabo P., Bolognese L., Briani M., Cacciavillani L., Calabrese A., Calabro P., Caliendo L., Calo L., Casella G., Casu G., Cavallini C., Ciampi Q., Ciccone M., Comito M., Corrada E., Crea F., D'Andrea A., D'Urbano M., De Caterina R., De Ferrari G., De Ponti R., Della Mattia A., DI Mario C., Donnazzan L., Esposito G., Fedele F., Ferraro A., Galasso G., Galie N., Gnecchi M., Golino P., Golia B., Guarini P., Leonardi S., Locuratolo N., Luzza F., Manganiello V., Francesca Marchetti M., Marenzi G., Margonato A., Meloni L., Metra M., Milo M., Mongiardo A., Monzo L., Morisco C., Novo G., Pancaldi S., Parollo M., Paterno G., Patti G., Priori S., Ravera A., Giuseppe Rebuzzi A., Rossi M., Scherillo M., Semprini F., Senni M., Sibilio G., Siviglia M., Tamburino C., Tortorici G., Versace F., Villari B., and Volpe M.
- Abstract
Aims: To evaluate the impact of the COVID-19 pandemic on patient admissions to Italian cardiac care units (CCUs). Methods and Results: We conducted a multicentre, observational, nationwide survey to collect data on admissions for acute myocardial infarction (AMI) at Italian CCUs throughout a 1 week period during the COVID-19 outbreak, compared with the equivalent week in 2019. We observed a 48.4% reduction in admissions for AMI compared with the equivalent week in 2019 (P < 0.001). The reduction was significant for both ST-segment elevation myocardial infarction [STEMI; 26.5%, 95% confidence interval (CI) 21.7-32.3; P = 0.009] and non-STEMI (NSTEMI; 65.1%, 95% CI 60.3-70.3; P < 0.001). Among STEMIs, the reduction was higher for women (41.2%; P = 0.011) than men (17.8%; P = 0.191). A similar reduction in AMI admissions was registered in North Italy (52.1%), Central Italy (59.3%), and South Italy (52.1%). The STEMI case fatality rate during the pandemic was substantially increased compared with 2019 [risk ratio (RR) = 3.3, 95% CI 1.7-6.6; P < 0.001]. A parallel increase in complications was also registered (RR = 1.8, 95% CI 1.1-2.8; P = 0.009). Conclusion: Admissions for AMI were significantly reduced during the COVID-19 pandemic across Italy, with a parallel increase in fatality and complication rates. This constitutes a serious social issue, demanding attention by the scientific and healthcare communities and public regulatory agencies.
- Published
- 2020
31. Grey zones on valvular heart disease: Interventional cardiology versus cardiac surgery. Expert opinion [Grey zones sulla cardiologia interventistica valvolare e cardiochirurgia a confronto. Opinioni degli esperti]
- Author
-
Frigerio, M, Fiocca, L, Bedogni, F, Alfieri, O, Margonato, A, Galletti, L, Indolfi, C, Senni, M, Grigioni, F, Frigerio M, Fiocca L, Bedogni F, Alfieri O, Margonato A, Galletti L, Indolfi C, Senni M, Grigioni F, Frigerio, M, Fiocca, L, Bedogni, F, Alfieri, O, Margonato, A, Galletti, L, Indolfi, C, Senni, M, Grigioni, F, Frigerio M, Fiocca L, Bedogni F, Alfieri O, Margonato A, Galletti L, Indolfi C, Senni M, and Grigioni F
- Abstract
Clinical guidelines, while representing an objective reference to perform correct therapeutic choices, contain grey zones, where recommendations are not supported by solid evidence. In a conference held in Bergamo in October 2018, an attempt was made to highlight some of the main grey zones in Cardiology and, through a comparison between experts, to draw shared conclusions that can illuminate our clinical practice. This manuscript contains the statements of the symposium concerning the controversies in the percutaneous treatment of valvulopathies. The first topic concerns the durability of aortic bioprostheses, comparing percutaneous interventional with surgical experiences. The second issue examines the opportunity to extend percutaneous aortic replacement as standard care to low-risk patients. The last gap in evidence concerns the percutaneous treatment of functional mitral valve insufficiency, with the MitraClip system. The work has also been implemented with evidences deriving from important randomized studies published after the date of the Conference.
- Published
- 2020
32. [GISE (Italian Society of Interventional Cardiology) Position paper: Short-term hospitalization for percutaneous coronary intervention; a helpful tool to manage post-COVID-19 backlogs]
- Author
-
Violini, R., De Rosa, S., Leonardi, S., Doronzo, B., Cremonesi, A., Callea, G., Spandonaro, F., Tarantini, G., Esposito, G., Cernetti, C., Indolfi, C., Berti, S., Marchese, A., Saia, F., and Monti, F.
- Subjects
Hospitalization ,Percutaneous Coronary Intervention ,Cardiology ,COVID-19 ,Humans ,Length of Stay ,Pandemics - Abstract
Minimization of hospital lengths of stay has always been a key goal for healthcare systems. More so during the current COVID-19 pandemic. In fact, we have faced a reduction in no-COVID-19 admissions with the generation of huge backlogs. Low-risk patients undergoing elective percutaneous coronary intervention (PCI) can be candidate for short-term hospitalization, with consequent reduction of waiting lists. Several single-center and multicenter observational studies, multiple randomized trials and some meta-analyses have addressed this topic.In this position paper, we present a proposal for short hospitalization for elective PCI procedures in selected patients who present complications only exceptionally and exclusively immediately after the procedure, if the inclusion and exclusion criteria are met. Each Center can choose between admission in day surgery or one day surgery, extending hospital length of stay only for patients who present complications or who are candidate for urgent surgery. Short-term hospitalization considerably reduces costs even if, with the current model, it generally results in a parallel reduction in reimbursement. Hence, we present an actual model, already tested successfully in an Italian hospital, that warrants sustainability. This approach can then be tailored to single Centers.
- Published
- 2022
33. Development of Disposables and Accessories for ROSES and Their In Vitro Experimentation
- Author
-
Danieli, G., Greco, P. F., Larocca, G., De Rosa, S., Indolfi, C., Polimeni, A., Massetti, Massimo, Tinelli, Giovanni, Tshomba, Yamume, Venturini, L., Massetti M. (ORCID:0000-0002-7100-8478), Tinelli G. (ORCID:0000-0002-2212-3226), Tshomba Y. (ORCID:0000-0001-7304-7553), Danieli, G., Greco, P. F., Larocca, G., De Rosa, S., Indolfi, C., Polimeni, A., Massetti, Massimo, Tinelli, Giovanni, Tshomba, Yamume, Venturini, L., Massetti M. (ORCID:0000-0002-7100-8478), Tinelli G. (ORCID:0000-0002-2212-3226), and Tshomba Y. (ORCID:0000-0001-7304-7553)
- Abstract
This paper describes the development of the disposables and accessories for ROSES (Robotic System for Endovascular Surgery). Initially developed exclusively for transcatheter percutaneous coronary angioplasty, it was later modified, initially leaving the components for angioplasty substantially unchanged to extend its use to endovascular transcatheter surgery. These disposables are used to translate gear rotations into catheter or guide wire advancement or retraction and rotation of their body through friction wheels. The use of a new cart was necessary for endovascular surgery, to which a system to measure forces opposed by the patient’s body to catheter advancement was added. Moreover, since some endovascular catheters present with large diameters, minor mechanical modifications were also performed on the robot actuator (RA), previously defined as a slave, in order to allow large catheters to be pushed, such as those needed for the repair of some big aneurysms or for TAVI. However, in doing this, the possibility of separating the disposables into two components, upper and lower, was found, which allows the extraction of the disposable without having to remove the catheter or guide wire already positioned. Finally, the disposables, whose development is illustrated here, were subjected to various versions and tests and the results are reported.
- Published
- 2022
34. Acute clinical presentation of nonischemic cardiomyopathies: early detection by cardiovascular magnetic resonance
- Author
-
Todiere, G., Barison, A., Baritussio, A., Cipriani, A., Guaricci, A.I., Pica, S., Indolfi, C., Pontone, G., and Dellegrottaglie, S.
- Subjects
Settore MED/11 - Malattie dell'Apparato Cardiovascolare ,General Medicine ,Cardiology and Cardiovascular Medicine - Published
- 2022
35. Focus on relevant aspects of 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
- Author
-
Spaccarotella C., Indolfi C., Spaccarotella, C., and Indolfi, C.
- Subjects
Electrocardiography ,Platelet Aggregation Inhibitor ,Arrhythmias, Cardiac ,Acute Coronary Syndrome ,Human - Published
- 2021
36. Position paper of the Italian Society of Cardiology (SIC) on COVID-19 vaccine priority in patients with cardiovascular diseases
- Author
-
Indolfi C., Barilla F., Basso C., Ciccone M. M., Curcio A., Mancone M., Mercuro G., Muscoli S., Nodari S., Pedrinelli R., Sinagra G., Filardi P. P., Romeo F., Indolfi, C., Barilla, F., Basso, C., Ciccone, M. M., Curcio, A., Mancone, M., Mercuro, G., Muscoli, S., Nodari, S., Pedrinelli, R., Romeo, F., Sinagra, G., and Filardi, P. P.
- Subjects
Cardiovascular diseases ,COVID-19 ,SARS-CoV-2 ,Vaccine ,Age Factors ,Animals ,COVID-19 Vaccines ,Cardiology ,Cardiovascular Diseases ,Coronary Disease ,Disease Vectors ,Heart Failure ,Heart Transplantation ,Heart Valve Diseases ,Humans ,Hypertension, Pulmonary ,Italy ,Prognosis ,Renal Insufficiency ,Societies, Medical ,Vaccines, Synthetic ,Consensus ,Prognosi ,COVID-19 Vaccine ,Medical ,Age Factor ,Disease Vector ,Vaccines ,Animal ,Synthetic ,Pulmonary ,Cardiovascular disease ,Heart Valve Disease ,Hypertension ,Societies ,Human - Abstract
In over a year, the COVID-19 pandemic caused 2.69 million deaths and 122 million infections. Social isolation and distancing measures have been the only prevention available for months. Scientific research has done a great deal of work, developing in a few months safe and effective vaccines against COVID-19. In the European Union, nowadays, four vaccines have been authorized for use: Pfizer-BioNTech, Moderna, ChAdOx1 (AstraZeneca/Oxford), Janssen (Johnson & Johnson), and three others are currently under rolling review. Vaccine allocation policy is crucial to optimize the advantage of treatment preferring people with the highest risk of contagion. These days the priority in the vaccination program is of particular importance since it has become clear that the number of vaccines is not sufficient for the entire Italian population in the short term. Cardiovascular diseases are frequently associated with severe COVID-19 infections, leading to the worst prognosis. The elderly population suffering from cardiovascular diseases is, therefore, to be considered a particularly vulnerable population. However, age cannot be considered the only discriminating factor because in the young-adult population suffering from severe forms of heart disease, the prognosis, if affected by COVID-19, is particularly ominous and these patients should have priority access to the vaccination program. The aim of this position paper is to establish a consensus on a priority in the vaccination of COVID-19 among subjects suffering from different cardiovascular diseases.
- Published
- 2021
37. Evaluation and percutaneous treatment of severely calcified coronary lesions
- Author
-
Ando G., Vizzari G., Niccoli G., Calabro P., Zimarino M., Spaccarotella C., De Rosa S., Piccolo R., Gragnano F., Mancone M., Muscoli S., Romeo F., Indolfi C., Ando, G., Vizzari, G., Niccoli, G., Calabro, P., Zimarino, M., Spaccarotella, C., De Rosa, S., Piccolo, R., Gragnano, F., Mancone, M., Muscoli, S., Romeo, F., and Indolfi, C.
- Subjects
Atherectomy, Coronary ,Treatment Outcome ,Lithotripsy ,Coronary Artery Disease ,Balloon angioplasty ,Coronary atherectomy ,Vascular Calcification ,Coronary Angiography ,Severity of Illness Index ,Human ,Percutaneous coronary intervention - Abstract
Patients with severely calcified coronary lesions undergoing percutaneous revascularization have a substantial risk of adverse outcomes, both during the procedure and in the long term. Over the last decade, a renewed interest has been observed about devices for plaque modification and lesion preparation, new technologies have been introduced in clinical practice and well-known devices have undergone technical and procedural improvements. The available tools for intravascular imaging allow a detailed evaluation of the calcific plaques within all the layers of the vessel wall. The complementary use of all these tools is ultimately aimed at optimizing the mechanics of balloon angioplasty and the delivery and expansion of drug-eluting stents. It has been fully demonstrated that rotational atherectomy improves procedural success when treating heavily calcified lesions. Intravascular lithotripsy, techniques and materials used during complex procedures such as chronic total occlusions, increasing operators' experience, as well as new drug-eluting stents with excellent mechanical characteristics, have further contributed to the feasibility and the safety of treating most fibrotic and heavily calcified vessels. We finally propose an algorithm for evaluation and treatment of severely calcific coronary lesions to demonstrate how such percutaneous revascularization procedures are planned and performed.
- Published
- 2021
38. Reperfusion therapies and in-hospital outcomes for ST-elevation myocardial infarction in europe. the ACVC-EAPCI EORP STEMI registry of the european society of cardiology
- Author
-
Zeymer, U., Ludman, P., Danchin, N., Kala, P., Laroche, C., Sadeghi, M., Caporale, R., Shaheen, S. M., Legutko, J., Iakobsishvili, Z., Alhabib, K. F., Motovska, Z., Studencan, M., Mimoso, J., Becker, D., Alexopoulos, D., Kereseselidze, Z., Stojkovic, S., Zelveian, P., Goda, A., Mirrakhimov, E., Bajraktari, G., Al-Farhan, H., Serpytis, P., Raungaard, B., Marandi, T., Moore, A. M., Quinn, M., Karjalainen, P. P., Tatu-Chitolu, G., Gale, C. P., Maggioni, A. P., Weidinger, F., Sinnaeve, P., Ferrari, R., Karamfilov, K., Lidon, R. -M., Kereselidze, Z., Iakobishvili, Z., Erglis, A., Kedev, S., Dudek, D., Tatu-Chitoiu, G., Shlyakhto, E., Bunc, M., Mourali, M. S., Konte, M., Larras, F., Lefrancq, E. F., Mekhaldi, S., Shuka, N., Pavli, E., Tafaj, E., Gishto, T., Dibra, A., Duka, A., Gjana, A., Kristo, A., Knuti, G., Demiraj, A., Dado, E., Hasimi, E., Simoni, L., Siqeca, M., Sisakian, H., Hayrapetyan, H., Markosyan, S., Galustyan, L., Arustamyan, N., Kzhdryan, H., Pepoyan, S., Zirkik, A., Von Lewinski, D., Paetzold, S., Kienzl, I., Matyas, K., Neunteufl, T., Nikfardjam, M., Neuhold, U., Mihalcz, A., Glaser, F., Steinwender, C., Reiter, C., Grund, M., Hrncic, D., Hoppe, U., Hammerer, M., Hinterbuchner, L., Hengstenberg, C., Delle Karth, G., Lang, I., Winkler, W., Hasun, M., Kastner, J., Havel, C., Derntl, M., Oberegger, G., Hajos, J., Adlbrecht, C., Publig, T., Leitgeb, M. -C., Wilfing, R., Jirak, P., C. -Y., Ho, Puskas, L., Schrutka, L., Spinar, J., Parenica, J., Hlinomaz, O., Fendrychova, V., Semenka, J., Sikora, J., Sitar, J., Groch, L., Rezek, M., Novak, M., Kramarikova, P., Stasek, J., Dusek, J., Zdrahal, P., Polasek, R., Karasek, J., Seiner, J., Sukova, N., Varvarovsky, I., Lazarak, T., Novotny, V., Matejka, J., Rokyta, R., Volovar, S., Belohlavek, J., Siranec, M., Kamenik, M., Kralik, R., Ravkilde, J., Jensen, S. E., Villadsen, A., Villefrance, K., Schmidt Skov, C., Maeng, M., Moeller, K., Hasan-Ali, H., Ahmed, T. A., Hassan, M., Elguindy, A., Farouk Ismail, M., Ibrahim Abd El-Aal, A., El-Sayed Gaafar, A., Magdy Hassan, H., Ahmed Shafie, M., Nabil El-Khouly, M., Bendary, A., Darwish, M., Ahmed, Y., Amin, O. A., Abdelhakim, A., Abosaif, K., Kandil, H., Galal, M. A. G., El Hefny, E. E., El Sayed, M., Aly, K., Mokarrab, M., Osman, M., Abdelhamid, M., Mantawy, S., Ali, M. R., Kaky, S. D., Khalil, V. A., Saraya, M. E. A., Talaat, A., Nabil, M., Mounir, W. M., Mahmoud, K., Aransa, A., Kazamel, G., Anwar, S., Al-Habbaa, A., Abd El Monem, M., Ismael, A., Amin Abu-Sheaishaa, M., Abd Rabou, M. M., Hammouda, T. M. A., Moaaz, M., Elkhashab, K., Ragab, T., Rashwan, A., Rmdan, A., Abdelrazek, G., Ebeid, H., Soliman Ghareeb, H., Farag, N., Zaki, M., Seleem, M., Torki, A., Youssef, M., Allah Nasser, N. A., Rafaat, A., Selim, H., Makram, M. M., Khayyal, M., Malasi, K., Madkour, A., Kolib, M., Alkady, H., Nagah, H., Yossef, M., Wafa, A., Mahfouz, E., Faheem, G., Magdy Moris, M., Ragab, A., Ghazal, M., Mabrouk, A., El-Masry, M., Naseem, M., Samir, S., Reinmets, J., Allvee, M., Saar, A., Ainla, T., Vaide, A., Kisseljova, M., Pakosta, U., Eha, J., Lotamois, K., Sia, J., Myllymaki, J., Pinola, T., Paana, T., Mikkelsson, J., Ampio, M., Tsivilasvili, J., Zurab, P., Agladze, R., Melia, A., Gogoberidze, D., Khubua, N., Totladze, L., Metreveli, I., Chikovani, A., Eitel, I., Poss, J., Werner, M., Constantz, A., Ahrens, C., Tolksdorf, H., Klinger, S., Sack, S., Heer, T., Lekakis, J., Kanakakis, I., Xenogiannis, I., Ermidou, K., Makris, N., Ntalianis, A., Katsaros, F., Revi, E., Kafkala, K., Mihelakis, E., Diakakis, G., Grammatikopoulos, K., Voutsinos, D., Xanthopoulou, I., Mplani, V., Foussas, S., Papakonstantinou, N., Patsourakos, N., Dimopoulos, A., Derventzis, A., Athanasiou, K., Vassilikos, V. P., Papadopoulos, C., Tzikas, S., Vogiatzis, I., Datsios, A., Galitsianos, I., Koutsampasopoulos, K., Grigoriadis, S., Douras, A., Baka, N., Spathis, S., Kyrlidis, T., Hatzinikolaou, H., Kiss, R. G., Nowotta, F., Toth, K., Szabo, S., Lakatos, C., Jambrik, Z., Ruzsa, J., Ruzsa, Z., Rona, S., Toth, J., Vargane Kosik, A., Toth, K. S. B., Nagy, G. G., Ondrejko, Z., Koromi, Z., Botos, B., Pourmoghadas, M., Salehi, A., Massoumi, G., Soleimani, A., Sarrafzadegan, N., Roohafza, H., Azarm, M., Mirmohammadsadeghi, A., Rajabi, D., Rahmani, Y., Siabani, S., Najafi, F., Hamzeh, B., Karim, H., Siabani, H., Saleh, N., Charehjoo, H., Zamzam, L., Al-Temimi, G., Al-Yassin, A., Mohammad, A., Ridha, A., Al-Saedi, G., Atabi, N., Sabbar, O., Mahmood, S., Dakhil, Z., Yaseen, I. F., Almyahi, M., Alkenzawi, H., Alkinani, T., Alyacopy, A., Kearney, P., Twomey, K., Shlomo, N., Beigel, R., Caldarola, P., Rutigliano, D., Sublimi Saponetti, L., Locuratolo, N., Palumbo, V., Scherillo, M., Formigli, D., Canova, P., Musumeci, G., Roncali, F., Metra, M., Lombardi, C., Visco, E., Rossi, L., Meloni, L., Montisci, R., Pippia, V., Marchetti, M. F., Congia, M., Cacace, C., Luca, G., Boscarelli, G., Indolfi, C., Ambrosio, G., Mongiardo, A., Spaccarotella, C., De Rosa, S., Canino, G., Critelli, C., Chiappetta, D., Battista, F., Gabrielli, D., Marziali, A., Bernabo, P., Navazio, A., Guerri, E., Manca, F., Gobbi, M., Oreto, Giuseppe, Andò, Giuseppe, Carerj, Scipione, Saporito, Francesco, Cimmino, Michele, Rigo, F., Zuin, G., Tuccillo, B., Scotto DI Uccio, F., Irace, L., Lorenzoni, G., Meloni, I., Merella, P., Polizzi, G. M., Pino, R., Marzilli, M., Morrone, D., Caravelli, P., Orsini, E., Mosa, S., Piovaccari, G., Santarelli, A., Cavazza, C., Romeo, F., Fedele, F., Mancone, M., Straito, M., Salvi, N., Scarparo, P., Severino, P., Razzini, C., Massaro, G., Cinque, A., Gaudio, C., Barilla, F., Torromeo, C., Porco, L., Mei, M., Iorio, R., Nassiacos, D., Barco, B., Sinagra, G., Falco, L., Priolo, L., Perkan, A., Strana, M., Percuku, L., Berisha, G., Mziu, B., Beishenkulov, M., Abdurashidova, T., Toktosunova, A., Kaliev, K., Serpytis, R., Butkute, E., Lizaitis, M., Broslavskyte, M., Xuereb, R. G., Mercieca Balbi, M., Paris, E., Buttigieg, L., Musial, W., Dobrzycki, S., Dubicki, A., Kazimierczyk, E., Tycinska, A., Wojakowski, W., Kalanska-Lukasik, B., Ochala, A., Wanha, W., Dworowy, S., Sielski, J., Janion, M., Janion-Sadowska, A., Wojtasik-Bakalarz, J., Bryniarski, L., Peruga, J. Z., Jonczyk, M., Jankowski, L., Klecha, A., Michalowska, J., Brzezinski, M., Kozmik, T., Kowalczyk, T., Adamczuk, J., Maliszewski, M., Kuziemka, P., Plaza, P., Jaros, A., Pawelec, A., Sledz, J., Bartus, S., Zmuda, W., Bogusz, M., Wisnicki, M., Szastak, G., Adamczyk, M., Suska, M., Czunko, P., Opolski, G., Kochman, J., Tomaniak, M., Miernik, S., Paczwa, K., Witkowski, A., Opolski, M. P., Staruch, A. D., Kalarus, Z., Honisz, G., Mencel, G., Swierad, M., Podolecki, T., Marques, J., Azevedo, P., Pereira, M. A., Gaspar, A., Monteiro, S., Goncalves, F., Leite, L., Manuel Lopes Dos Santos, W., Amado, J., Pereira, D., Silva, B., Caires, G., Neto, M., Rodrigues, R., Correia, A., Freitas, D., Lourenco, A., Ferreira, F., Sousa, F., Portugues, J., Calvo, L., Almeida, F., Alves, M., Silva, A., Caria, R., Seixo, F., Militaru, C., Ionica, E., Istratoaie, O., Florescu, M., Lipnitckaia, E., Osipova, O., Konstantinov, S., Bukatov, V., Vinokur, T., Egorova, E., Nefedova, E., Levashov, S., Gorbunova, A., Redkina, M., Karaulovskaya, N., Bijieva, F., Babich, N., Smirnova, O., Filyanin, R., Eseva, S., Kutluev, A., Chlopenova, A., Shtanko, A., Kuppar, E., Shaekhmurzina, E., Ibragimova, M., Mullahmetova, M., Chepisova, M., Kuzminykh, M., Betkaraeva, M., Namitokov, A., Khasanov, N., Baleeva, L., Galeeva, Z., Magamedkerimova, F., Ivantsov, E., Tavlueva, E., Kochergina, A., Sedykh, D., Kosmachova, E., Skibitskiy, V., Porodenko, N., Litovka, K., Ulbasheva, E., Niculina, S., Petrova, M., Harkov, E., Tsybulskaya, N., Lobanova, A., Chernova, A., Kuskaeva, A., Kuskaev, A., Ruda, M., Zateyshchikov, D., Gilarov, M., Konstantinova, E., Koroleva, O., Averkova, A., Zhukova, N., Kalimullin, D., Borovkova, N., Tokareva, A., Buyanova, M., Khaisheva, L., Pirozhenko, A., Novikova, T., Yakovlev, A., Tyurina, T., Lapshin, K., Moroshkina, N., Kiseleva, M., Fedorova, S., Krylova, L., Duplyakov, D., Semenova, Y., Rusina, A., Ryabov, V., Syrkina, A., Demianov, S., Reitblat, O., Artemchuk, A., Efremova, E., Makeeva, E., Menzorov, M., Shutov, A., Klimova, N., Shevchenko, I., Elistratova, O., Kostyuckova, O., Islamov, R., Budyak, V., Ponomareva, E., Ullah Jan, U., Alshehri, A. M., Sedky, E., Alsihati, Z., Mimish, L., Selem, A., Malik, A., Majeed, O., Altnji, I., Alshehri, M., Aref, A., Alhabib, K., Aldosary, M., Tayel, S., Abd Alrahman, M., Asfina, K. N., Abdin Hussein, G., Butt, M., Markovic Nikolic, N., Obradovic, S., Djenic, N., Brajovic, M., Davidovic, A., Romanovic, R., Novakovic, V., Dekleva, M., Spasic, M., Dzudovic, B., Jovic, Z., Cvijanovic, D., Veljkovic, S., Ivanov, I., Cankovic, M., Jarakovic, M., Kovacevic, M., Trajkovic, M., Mitov, V., Jovic, A., Hudec, M., Gombasky, M., Sumbal, J., Bohm, A., Baranova, E., Kovar, F., Samos, M., Podoba, J., Kurray, P., Obona, T., Remenarikova, A., Kollarik, B., Verebova, D., Kardosova, G., Alusik, D., Macakova, J., Kozlej, M., Bayes-Genis, A., Sionis, A., Garcia Garcia, C., Duran Cambra, A., Labata Salvador, C., Rueda Sobella, F., Sans Rosello, J., Vila Perales, M., Oliveras Vila, T., Ferrer Massot, M., Baneras, J., Lekuona, I., Zugazabeitia, G., Fernandez-Ortiz, A., Viana Tejedor, A., Ferrera, C., Alvarez, V., DIaz-Castro, O., Agra-Bermejo, R. M., Gonzalez-Cambeiro, C., Gonzalez-Babarro, E., Domingo-Del Valle, J., Royuela, N., Burgos, V., Canteli, A., Castrillo, C., Cobo, M., Ruiz, M., Abu-Assi, E., Garcia Acuna, J., Zeymer, U., Ludman, P., Danchin, N., Kala, P., Laroche, C., Sadeghi, M., Caporale, R., Shaheen, S. M., Legutko, J., Iakobsishvili, Z., Alhabib, K. F., Motovska, Z., Studencan, M., Mimoso, J., Becker, D., Alexopoulos, D., Kereseselidze, Z., Stojkovic, S., Zelveian, P., Goda, A., Mirrakhimov, E., Bajraktari, G., Al-Farhan, H., Serpytis, P., Raungaard, B., Marandi, T., Moore, A. M., Quinn, M., Karjalainen, P. P., Tatu-Chitolu, G., Gale, C. P., Maggioni, A. P., Weidinger, F., Sinnaeve, P., Ferrari, R., Karamfilov, K., Lidon, R. -M., Kereselidze, Z., Iakobishvili, Z., Erglis, A., Kedev, S., Dudek, D., Tatu-Chitoiu, G., Shlyakhto, E., Bunc, M., Mourali, M. S., Konte, M., Larras, F., Lefrancq, E. F., Mekhaldi, S., Shuka, N., Pavli, E., Tafaj, E., Gishto, T., Dibra, A., Duka, A., Gjana, A., Kristo, A., Knuti, G., Demiraj, A., Dado, E., Hasimi, E., Simoni, L., Siqeca, M., Sisakian, H., Hayrapetyan, H., Markosyan, S., Galustyan, L., Arustamyan, N., Kzhdryan, H., Pepoyan, S., Zirkik, A., Von Lewinski, D., Paetzold, S., Kienzl, I., Matyas, K., Neunteufl, T., Nikfardjam, M., Neuhold, U., Mihalcz, A., Glaser, F., Steinwender, C., Reiter, C., Grund, M., Hrncic, D., Hoppe, U., Hammerer, M., Hinterbuchner, L., Hengstenberg, C., Delle Karth, G., Lang, I., Winkler, W., Hasun, M., Kastner, J., Havel, C., Derntl, M., Oberegger, G., Hajos, J., Adlbrecht, C., Publig, T., Leitgeb, M. -C., Wilfing, R., Jirak, P., Ho, C. -Y., Puskas, L., Schrutka, L., Spinar, J., Parenica, J., Hlinomaz, O., Fendrychova, V., Semenka, J., Sikora, J., Sitar, J., Groch, L., Rezek, M., Novak, M., Kramarikova, P., Stasek, J., Dusek, J., Zdrahal, P., Polasek, R., Karasek, J., Seiner, J., Sukova, N., Varvarovsky, I., Lazarak, T., Novotny, V., Matejka, J., Rokyta, R., Volovar, S., Belohlavek, J., Siranec, M., Kamenik, M., Kralik, R., Ravkilde, J., Jensen, S. E., Villadsen, A., Villefrance, K., Schmidt Skov, C., Maeng, M., Moeller, K., Hasan-Ali, H., Ahmed, T. A., Hassan, M., Elguindy, A., Farouk Ismail, M., Ibrahim Abd El-Aal, A., El-Sayed Gaafar, A., Magdy Hassan, H., Ahmed Shafie, M., Nabil El-Khouly, M., Bendary, A., Darwish, M., Ahmed, Y., Amin, O. A., Abdelhakim, A., Abosaif, K., Kandil, H., Galal, M. A. G., El Hefny, E. E., El Sayed, M., Aly, K., Mokarrab, M., Osman, M., Abdelhamid, M., Mantawy, S., Ali, M. R., Kaky, S. D., Khalil, V. A., Saraya, M. E. A., Talaat, A., Nabil, M., Mounir, W. M., Mahmoud, K., Aransa, A., Kazamel, G., Anwar, S., Al-Habbaa, A., Abd El Monem, M., Ismael, A., Amin Abu-Sheaishaa, M., Abd Rabou, M. M., Hammouda, T. M. A., Moaaz, M., Elkhashab, K., Ragab, T., Rashwan, A., Rmdan, A., Abdelrazek, G., Ebeid, H., Soliman Ghareeb, H., Farag, N., Zaki, M., Seleem, M., Torki, A., Youssef, M., Allah Nasser, N. A., Rafaat, A., Selim, H., Makram, M. M., Khayyal, M., Malasi, K., Madkour, A., Kolib, M., Alkady, H., Nagah, H., Yossef, M., Wafa, A., Mahfouz, E., Faheem, G., Magdy Moris, M., Ragab, A., Ghazal, M., Mabrouk, A., El-Masry, M., Naseem, M., Samir, S., Reinmets, J., Allvee, M., Saar, A., Ainla, T., Vaide, A., Kisseljova, M., Pakosta, U., Eha, J., Lotamois, K., Sia, J., Myllymaki, J., Pinola, T., Paana, T., Mikkelsson, J., Ampio, M., Tsivilasvili, J., Zurab, P., Agladze, R., Melia, A., Gogoberidze, D., Khubua, N., Totladze, L., Metreveli, I., Chikovani, A., Eitel, I., Poss, J., Werner, M., Constantz, A., Ahrens, C., Tolksdorf, H., Klinger, S., Sack, S., Heer, T., Lekakis, J., Kanakakis, I., Xenogiannis, I., Ermidou, K., Makris, N., Ntalianis, A., Katsaros, F., Revi, E., Kafkala, K., Mihelakis, E., Diakakis, G., Grammatikopoulos, K., Voutsinos, D., Xanthopoulou, I., Mplani, V., Foussas, S., Papakonstantinou, N., Patsourakos, N., Dimopoulos, A., Derventzis, A., Athanasiou, K., Vassilikos, V. P., Papadopoulos, C., Tzikas, S., Vogiatzis, I., Datsios, A., Galitsianos, I., Koutsampasopoulos, K., Grigoriadis, S., Douras, A., Baka, N., Spathis, S., Kyrlidis, T., Hatzinikolaou, H., Kiss, R. G., Nowotta, F., Toth, K., Szabo, S., Lakatos, C., Jambrik, Z., Ruzsa, J., Ruzsa, Z., Rona, S., Toth, J., Vargane Kosik, A., Toth, K. S. B., Nagy, G. G., Ondrejko, Z., Koromi, Z., Botos, B., Pourmoghadas, M., Salehi, A., Massoumi, G., Soleimani, A., Sarrafzadegan, N., Roohafza, H., Azarm, M., Mirmohammadsadeghi, A., Rajabi, D., Rahmani, Y., Siabani, S., Najafi, F., Hamzeh, B., Karim, H., Siabani, H., Saleh, N., Charehjoo, H., Zamzam, L., Al-Temimi, G., Al-Yassin, A., Mohammad, A., Ridha, A., Al-Saedi, G., Atabi, N., Sabbar, O., Mahmood, S., Dakhil, Z., Yaseen, I. F., Almyahi, M., Alkenzawi, H., Alkinani, T., Alyacopy, A., Kearney, P., Twomey, K., Shlomo, N., Beigel, R., Caldarola, P., Rutigliano, D., Sublimi Saponetti, L., Locuratolo, N., Palumbo, V., Scherillo, M., Formigli, D., Canova, P., Musumeci, G., Roncali, F., Metra, M., Lombardi, C., Visco, E., Rossi, L., Meloni, L., Montisci, R., Pippia, V., Marchetti, M. F., Congia, M., Cacace, C., Luca, G., Boscarelli, G., Indolfi, C., Ambrosio, G., Mongiardo, A., Spaccarotella, C., De Rosa, S., Canino, G., Critelli, C., Chiappetta, D., Battista, F., Gabrielli, D., Marziali, A., Bernabo, P., Navazio, A., Guerri, E., Manca, F., Gobbi, M., Oreto, G., Ando, G., Carerj, S., Saporito, F., Cimmino, M., Rigo, F., Zuin, G., Tuccillo, B., Scotto DI Uccio, F., Irace, L., Lorenzoni, G., Meloni, I., Merella, P., Polizzi, G. M., Pino, R., Marzilli, M., Morrone, D., Caravelli, P., Orsini, E., Mosa, S., Piovaccari, G., Santarelli, A., Cavazza, C., Romeo, F., Fedele, F., Mancone, M., Straito, M., Salvi, N., Scarparo, P., Severino, P., Razzini, C., Massaro, G., Cinque, A., Gaudio, C., Barilla, F., Torromeo, C., Porco, L., Mei, M., Iorio, R., Nassiacos, D., Barco, B., Sinagra, G., Falco, L., Priolo, L., Perkan, A., Strana, M., Percuku, L., Berisha, G., Mziu, B., Beishenkulov, M., Abdurashidova, T., Toktosunova, A., Kaliev, K., Serpytis, R., Butkute, E., Lizaitis, M., Broslavskyte, M., Xuereb, R. G., Mercieca Balbi, M., Paris, E., Buttigieg, L., Musial, W., Dobrzycki, S., Dubicki, A., Kazimierczyk, E., Tycinska, A., Wojakowski, W., Kalanska-Lukasik, B., Ochala, A., Wanha, W., Dworowy, S., Sielski, J., Janion, M., Janion-Sadowska, A., Wojtasik-Bakalarz, J., Bryniarski, L., Peruga, J. Z., Jonczyk, M., Jankowski, L., Klecha, A., Michalowska, J., Brzezinski, M., Kozmik, T., Kowalczyk, T., Adamczuk, J., Maliszewski, M., Kuziemka, P., Plaza, P., Jaros, A., Pawelec, A., Sledz, J., Bartus, S., Zmuda, W., Bogusz, M., Wisnicki, M., Szastak, G., Adamczyk, M., Suska, M., Czunko, P., Opolski, G., Kochman, J., Tomaniak, M., Miernik, S., Paczwa, K., Witkowski, A., Opolski, M. P., Staruch, A. D., Kalarus, Z., Honisz, G., Mencel, G., Swierad, M., Podolecki, T., Marques, J., Azevedo, P., Pereira, M. A., Gaspar, A., Monteiro, S., Goncalves, F., Leite, L., Manuel Lopes Dos Santos, W., Amado, J., Pereira, D., Silva, B., Caires, G., Neto, M., Rodrigues, R., Correia, A., Freitas, D., Lourenco, A., Ferreira, F., Sousa, F., Portugues, J., Calvo, L., Almeida, F., Alves, M., Silva, A., Caria, R., Seixo, F., Militaru, C., Ionica, E., Istratoaie, O., Florescu, M., Lipnitckaia, E., Osipova, O., Konstantinov, S., Bukatov, V., Vinokur, T., Egorova, E., Nefedova, E., Levashov, S., Gorbunova, A., Redkina, M., Karaulovskaya, N., Bijieva, F., Babich, N., Smirnova, O., Filyanin, R., Eseva, S., Kutluev, A., Chlopenova, A., Shtanko, A., Kuppar, E., Shaekhmurzina, E., Ibragimova, M., Mullahmetova, M., Chepisova, M., Kuzminykh, M., Betkaraeva, M., Namitokov, A., Khasanov, N., Baleeva, L., Galeeva, Z., Magamedkerimova, F., Ivantsov, E., Tavlueva, E., Kochergina, A., Sedykh, D., Kosmachova, E., Skibitskiy, V., Porodenko, N., Litovka, K., Ulbasheva, E., Niculina, S., Petrova, M., Harkov, E., Tsybulskaya, N., Lobanova, A., Chernova, A., Kuskaeva, A., Kuskaev, A., Ruda, M., Zateyshchikov, D., Gilarov, M., Konstantinova, E., Koroleva, O., Averkova, A., Zhukova, N., Kalimullin, D., Borovkova, N., Tokareva, A., Buyanova, M., Khaisheva, L., Pirozhenko, A., Novikova, T., Yakovlev, A., Tyurina, T., Lapshin, K., Moroshkina, N., Kiseleva, M., Fedorova, S., Krylova, L., Duplyakov, D., Semenova, Y., Rusina, A., Ryabov, V., Syrkina, A., Demianov, S., Reitblat, O., Artemchuk, A., Efremova, E., Makeeva, E., Menzorov, M., Shutov, A., Klimova, N., Shevchenko, I., Elistratova, O., Kostyuckova, O., Islamov, R., Budyak, V., Ponomareva, E., Ullah Jan, U., Alshehri, A. M., Sedky, E., Alsihati, Z., Mimish, L., Selem, A., Malik, A., Majeed, O., Altnji, I., Alshehri, M., Aref, A., Alhabib, K., Aldosary, M., Tayel, S., Abd Alrahman, M., Asfina, K. N., Abdin Hussein, G., Butt, M., Markovic Nikolic, N., Obradovic, S., Djenic, N., Brajovic, M., Davidovic, A., Romanovic, R., Novakovic, V., Dekleva, M., Spasic, M., Dzudovic, B., Jovic, Z., Cvijanovic, D., Veljkovic, S., Ivanov, I., Cankovic, M., Jarakovic, M., Kovacevic, M., Trajkovic, M., Mitov, V., Jovic, A., Hudec, M., Gombasky, M., Sumbal, J., Bohm, A., Baranova, E., Kovar, F., Samos, M., Podoba, J., Kurray, P., Obona, T., Remenarikova, A., Kollarik, B., Verebova, D., Kardosova, G., Alusik, D., Macakova, J., Kozlej, M., Bayes-Genis, A., Sionis, A., Garcia Garcia, C., Duran Cambra, A., Labata Salvador, C., Rueda Sobella, F., Sans Rosello, J., Vila Perales, M., Oliveras Vila, T., Ferrer Massot, M., Baneras, J., Lekuona, I., Zugazabeitia, G., Fernandez-Ortiz, A., Viana Tejedor, A., Ferrera, C., Alvarez, V., DIaz-Castro, O., Agra-Bermejo, R. M., Gonzalez-Cambeiro, C., Gonzalez-Babarro, E., Domingo-Del Valle, J., Royuela, N., Burgos, V., Canteli, A., Castrillo, C., Cobo, M., Ruiz, M., Abu-Assi, E., and Garcia Acuna, J.
- Subjects
Registrie ,medicine.medical_specialty ,medicine.medical_treatment ,Cardiology ,Myocardial Reperfusion ,030204 cardiovascular system & hematology ,03 medical and health sciences ,Hospital ,0302 clinical medicine ,Reperfusion therapy ,Percutaneous Coronary Intervention ,Internal medicine ,Fibrinolysis ,medicine ,Humans ,030212 general & internal medicine ,Myocardial infarction ,Registries ,Prospective Studies ,Prospective cohort study ,Observational studies ,observational studies ,reperfusion therapy ,business.industry ,Mortality rate ,Primary percutaneous coronary intervention ,ST-elevation myocardial infarction ,Europe ,Hospitals ,Treatment Outcome ,ST Elevation Myocardial Infarction ,Percutaneous coronary intervention ,medicine.disease ,primary percutaneous coronary intervention ,Observational studie ,3. Good health ,Prospective Studie ,Cohort ,Conventional PCI ,Cardiology and Cardiovascular Medicine ,business ,Human - Abstract
Aims The aim of this study was to determine the contemporary use of reperfusion therapy in the European Society of Cardiology (ESC) member and affiliated countries and adherence to ESC clinical practice guidelines in patients with ST-elevation myocardial infarction (STEMI). Methods and results Prospective cohort (EURObservational Research Programme STEMI Registry) of hospitalized STEMI patients with symptom onset Conclusions The use of reperfusion therapy for STEMI in the ESC member and affiliated countries was high. Primary PCI was the most frequently used treatment and associated total in-hospital mortality was below 5%. However, there was geographic variation in the use of primary PCI, which was associated with differences in in-hospital mortality.
- Published
- 2021
39. The role of thermal effects in plasma medical applications: Biological and calorimetric analysis
- Author
-
Cordaro, L, De Masi, G, Fassina, A, Gareri, C, Pimazzoni, A, Desideri, D, Indolfi, C, Martines, E, Cordaro L., De Masi G., Fassina A., Gareri C., Pimazzoni A., Desideri D., Indolfi C., Martines E., Cordaro, L, De Masi, G, Fassina, A, Gareri, C, Pimazzoni, A, Desideri, D, Indolfi, C, Martines, E, Cordaro L., De Masi G., Fassina A., Gareri C., Pimazzoni A., Desideri D., Indolfi C., and Martines E.
- Abstract
Plasma Medicine tools exploit the therapeutic effects of the exposure of living matter to plasma produced at atmospheric pressure. Since these plasmas are usually characterized by a non-thermal equilibrium (highly energetic electrons, low temperature ions), thermal effects on the substrate are usually considered negligible. Conversely, reactive oxygen and nitrogen species (RONS), UV radiation and metastables are thought to play a major role. In this contribution, we compare the presence of thermal effects in different operational regimes (corresponding to different power levels) of the Plasma Coagulation Controller (PCC), a plasma source specifically designed for accelerating blood coagulation. In particular, we analyze the application of PCC on human blood samples (in vitro) and male Wistar rats tissues (in vivo). Histological analysis points out, for the highest applied power regime, the onset of detrimental thermal effects such as red cell lysis in blood samples and tissues damages in in-vivo experiments. Calorimetric bench tests performed on metallic targets show that the current coupled by the plasma on the substrate induces most of measured thermal loads through a resistive coupling. Furthermore, the distance between the PCC nozzle and the target is found to strongly affect the total power.
- Published
- 2019
40. International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER)
- Author
-
Beyer-Westendorf, J, Camm, A, Fox, K, Le Heuzey, J, Haas, S, Turpie, A, Virdone, S, Kakkar, A, Pieper, K, Kayani, G, Gersh, B, Hildebrandt, P, Dominguez, H, Comuth, W, Frost, L, Moller, D, Christensen, H, Bruun, L, Milhem, A, Gauthier, J, Mielot, C, Chanseaume, S, Chopra, S, Amlaiky, A, Tricot, O, Sierra, V, Dompnier, A, Zannad, N, Pinzani, A, Quatre, A, Mansourati, J, Fauchier, L, Badenco, N, Gandjbakhch, E, Chachoua, K, Malquarti, V, Pierron, F, Sacher, F, Taieb, J, Davy, J, Marijon, E, Lellouche, N, Leenhardt, A, Salem, A, Lesto, I, Muller, J, Garcia, R, Neau, J, Berneau, J, Schon, N, Gulba, D, Appel, K, Merke, J, Dshabrailov, J, Bauknecht, C, Scheuermann, O, Schroder, T, Jung, W, Kopf, A, Brachmann, J, Leschke, M, Taggeselle, J, Seige, M, Lassig, T, Appel, S, Schmiedl, M, Muller, K, Heinz, G, Axthelm, C, Eberhard, K, Hugl, B, Schwarz, T, Sechtem, U, Falanga, A, Rubino, V, Calo, L, Ageno, W, Massari, F, Imberti, D, Di Gennaro, L, Gaita, F, Margonato, A, Cannava, G, Capasso, F, Diemberger, I, Pelliccia, F, Cafolla, A, Bardari, S, Mattei, L, Ruocco, L, Boriani, G, Poli, D, Testa, S, Indolfi, C, Quintavalla, R, Mos, L, Ladyjanskaia, G, Aksoy, I, Van De Wetering, M, Theunissen, L, Den Hartog, F, Nijmeijer, R, Van De Wal, R, Reinders, S, Patterson, M, Melker, E, Troquay, R, Korecki, J, Szyszka, A, Diks, F, Sumis, J, Cygler, J, Miklaszewicz, B, Litwiejko-Pietrynczak, E, Napora, P, Drelich, G, Kawka-Urbanek, T, Wranicz, J, Mierzejewski, M, Drzewiecka, A, Wronska, D, Fares, I, Baska, J, Stania, K, Krzyzanowski, W, Miekus, P, Tyminski, M, Dronov, D, Zenin, S, Isaeva, E, Lopukhov, A, Yakusevich, V, Kuznetsov, D, Kameneva, T, Pokushalov, E, Karetnikova, V, Dik, I, Karpushina, I, Nikolin, D, Doletsky, A, Ardashev, A, Timofeeva, A, Miller, O, Lyamina, N, Shubik, Y, Boldueva, S, Blanco Coronado, J, Gonzalez Juanatey, C, Otero, E, Alonso, D, Torres Llergo, J, Gonzalez Lama, J, De Prada Tiffe, J, Garcia Seara, F, Gomez Doblas, J, Riancho, J, Clua-Espuny, J, Motero, J, Arrarte, V, Martin Raymondi, D, Isasti Aizpurua, G, Marin, F, Nieto, J, Fernandez Portales, J, Alvarez Garcia, P, Torstensson, I, Cederin, B, Kalm, T, Rosenqvist, U, Thulin, J, Hajimirsadeghi, A, Crisby, M, Manoj, A, Bakhai, A, Mistri, A, Krishnan, M, Kumar, S, Kirubakaran, S, Thomas, H, Camm, J, Ahmed, F, Ross, A, Barry, K, Stockwell, R, Broadley, A, Mamun, M, Chatterjee, K, Cooke, J, Mccready, J, Dutta, D, John, K, Pandya, P, Howlett, R, Vinson, P, Lim, Foley, P, Bruce, D, Dixit, A, Broughton, D, Taylor, J, Schilling, R, Leon, K, Saeed, K, Shaheen, S, Tawfik, M, Mortadda, A, Seleem, M, Aly, M, Kazamel, G, Elbadry, M, Kamal, S, Hassan, M, Mostafa, M, Medhat, M, Ekhlas, Ghaleb, R, Taha, M, Daoud, I, Al Din, H, Imam, A, El Hameed, M, Helmy, Al-Murayeh, M, Akhtar, N, Matto, B, Ghani, M, Amoudi, O, Morsy, M, Bashir, A, Al Hossni, Y, Al Ghamdi, B, Zia-Ul-Sabah, Mir, S, Dardir, D, Masswary, A, Al Shehri, A, Iqbal, J, Almansori, M, Venkitachalam, C, Kurian, J, Rao, J, Aisheh, A, Albawab, A, Subbaraman, B, Amanat, A, Esfehani, K, Lochan, R, Bin Brek, A, Mittal, B, Ghazi, Y, Krishna, M, Tabatabaei, S, Thoppil, P, Nasim, S, El Khider Nour, S, Barros, P, Almeida, A, Andrade, M, Garbelini, B, Silvestrini, T, Alves, A, De Lima, C, Kormann, A, De Lima, G, Halperin, C, Salvadori Junior, D, Freitas, A, Gemelli, J, Ornelas, C, Dantas, J, Aziz, J, Backes, L, Barroso, W, Paiva, M, De Figueiredo Neto, J, Dos Santos, F, De Lima Neto, J, Bergo, R, Salvador Junior, P, Lopez, A, Alva, J, Gamba, M, Padilla-Padilla, F, Ruiz, A, Berlingieri, J, Bakbak, A, Gupta, M, Saunders, K, Costa-Vitali, A, Beaudry, P, Bhargava, R, Khaykin, Y, Healey, J, Crystal, E, Nadeau, D, Begg, A, Anderson, C, Baveja, S, Cross, D, Catanchin, A, Brieger, D, Lim, K, Davidson, P, Tan, R, Bhindi, R, Hickey, J, Layland, J, Bloch, M, Itty, C, Singh, B, Carroll, P, Lee, A, Starmer, G, Lehman, R, Beyer-Westendorf J., Camm A. J., Fox K. A. A., Le Heuzey J. -Y., Haas S., Turpie A. G. G., Virdone S., Kakkar A. K., Pieper K. S., Kayani G., Gersh B. J., Hildebrandt P., Dominguez H., Comuth W., Frost L., Moller D. S., Christensen H., Bruun L. M., Milhem A., Gauthier J., Mielot C., Chanseaume S., Chopra S., Amlaiky A., Tricot O., Sierra V., Dompnier A., Zannad N., Pinzani A., Quatre A., Mansourati J., Fauchier L., Badenco N., Gandjbakhch E., Chachoua K. F., Malquarti V., Pierron F., Sacher F., Taieb J., Davy J. M., Marijon E., Lellouche N., Leenhardt A., Salem A., Lesto I., Muller J. J., Garcia R., Neau J. P., Berneau J. B., Schon N., Gulba D., Appel K. F., Merke J., Dshabrailov J., Bauknecht C., Scheuermann O., Schroder T., Jung W., Kopf A., Brachmann J., Leschke M., Taggeselle J., Seige M., Lassig T., Appel S., Schmiedl M., Muller K., Heinz G. U., Axthelm C., Eberhard K., Hugl B., Schwarz T., Sechtem U., Falanga A., Rubino V., Calo L., Ageno W., Massari F., Imberti D., Di Gennaro L., Gaita F., Margonato A., Cannava G., Capasso F., Diemberger I., Pelliccia F., Cafolla A., Bardari S., Mattei L., Ruocco L., Boriani G., Poli D., Testa S., Indolfi C., Quintavalla R., Mos L., Ladyjanskaia G., Aksoy I., Van De Wetering M., Theunissen L., Den Hartog F., Nijmeijer R., Van De Wal R., Reinders S., Patterson M., Melker E. D., Troquay R., Korecki J., Szyszka A., Diks F., Sumis J., Cygler J., Miklaszewicz B., Litwiejko-Pietrynczak E., Napora P., Drelich G., Kawka-Urbanek T., Wranicz J. K., Mierzejewski M., Drzewiecka A., Wronska D., Fares I., Baska J., Stania K., Krzyzanowski W., Miekus P., Tyminski M., Dronov D., Zenin S., Isaeva E., Lopukhov A., Yakusevich V., Kuznetsov D., Kameneva T., Pokushalov E., Karetnikova V., Dik I., Karpushina I., Nikolin D., Doletsky A., Ardashev A., Timofeeva A., Miller O., Lyamina N., Shubik Y., Boldueva S., Blanco Coronado J. L., Gonzalez Juanatey C., Otero E., Alonso D., Torres Llergo J., Gonzalez Lama J., De Prada Tiffe J. A. V., Garcia Seara F. J., Gomez Doblas J. J., Riancho J. A., Clua-Espuny J. L., Motero J., Arrarte V. I., Martin Raymondi D., Isasti Aizpurua G., Marin F., Nieto J. A., Fernandez Portales J., Alvarez Garcia P., Torstensson I., Cederin B., Kalm T., Rosenqvist U., Thulin J., Hajimirsadeghi A., Crisby M., Manoj A., Bakhai A., Mistri A., Krishnan M., Kumar S., Kirubakaran S., Thomas H., Camm J., Ahmed F., Ross A. M., Barry K., Stockwell R., Broadley A., Mamun M., Chatterjee K., Cooke J., McCready J., Dutta D., John K., Pandya P., Howlett R., Vinson P., Foley P., Bruce D., Dixit A., Broughton D., Taylor J., Schilling R., Leon K., Saeed K., Shaheen S., Tawfik M., Mortadda A., Seleem M., Aly M. S. I., Kazamel G., Elbadry M., Kamal S., Hassan M., Mostafa M., Medhat M. E. S., Ghaleb R., Taha M. O., Daoud I., Al Din H., Imam A. M., El Hameed M. A., Al-Murayeh M., Akhtar N., Matto B. M., Ghani M. A., Amoudi O. A., Morsy M. M., Bashir A. A. F., Al Hossni Y. M., Al Ghamdi B., Mir S., Dardir D., Masswary A., Al Shehri A. R., Iqbal J., Almansori M. A. J., Venkitachalam C. G., Kurian J., Rao J., Aisheh A., Albawab A. A., Subbaraman B., Amanat A., Esfehani K. J., Lochan R., Bin Brek A., Mittal B., Ghazi Y., Krishna M., Tabatabaei S. B., Thoppil P. S., Nasim S., El Khider Nour S., Barros P., Almeida A. P., Andrade M., Garbelini B., Silvestrini T. L., Alves A. R., De Lima C. E. B., Kormann A., De Lima G. G., Halperin C., Salvadori Junior D., Freitas A. F., Gemelli J. R., Ornelas C. E., Dantas J. M. M., Aziz J. L., Backes L. M., Barroso W. S., Paiva M. S., De Figueiredo Neto J. A., Dos Santos F. R., De Lima Neto J. A., Bergo R., Salvador Junior P. R., Lopez A. G., Alva J. C. P., Gamba M. A. A., Padilla-Padilla F. G., Ruiz A. E. B., Berlingieri J., Bakbak A., Gupta M., Saunders K., Costa-Vitali A., Beaudry P. R., Bhargava R., Khaykin Y., Healey J. S., Crystal E., Nadeau Dhillon, Begg A., Anderson C., Baveja S., Cross D., Catanchin A., Brieger D., Lim K. T., Davidson P., Tan R., Bhindi R., Hickey J., Layland J., Bloch M., Itty C., Singh B., Carroll P., Lee A., Starmer G., Lehman R., Beyer-Westendorf, J, Camm, A, Fox, K, Le Heuzey, J, Haas, S, Turpie, A, Virdone, S, Kakkar, A, Pieper, K, Kayani, G, Gersh, B, Hildebrandt, P, Dominguez, H, Comuth, W, Frost, L, Moller, D, Christensen, H, Bruun, L, Milhem, A, Gauthier, J, Mielot, C, Chanseaume, S, Chopra, S, Amlaiky, A, Tricot, O, Sierra, V, Dompnier, A, Zannad, N, Pinzani, A, Quatre, A, Mansourati, J, Fauchier, L, Badenco, N, Gandjbakhch, E, Chachoua, K, Malquarti, V, Pierron, F, Sacher, F, Taieb, J, Davy, J, Marijon, E, Lellouche, N, Leenhardt, A, Salem, A, Lesto, I, Muller, J, Garcia, R, Neau, J, Berneau, J, Schon, N, Gulba, D, Appel, K, Merke, J, Dshabrailov, J, Bauknecht, C, Scheuermann, O, Schroder, T, Jung, W, Kopf, A, Brachmann, J, Leschke, M, Taggeselle, J, Seige, M, Lassig, T, Appel, S, Schmiedl, M, Muller, K, Heinz, G, Axthelm, C, Eberhard, K, Hugl, B, Schwarz, T, Sechtem, U, Falanga, A, Rubino, V, Calo, L, Ageno, W, Massari, F, Imberti, D, Di Gennaro, L, Gaita, F, Margonato, A, Cannava, G, Capasso, F, Diemberger, I, Pelliccia, F, Cafolla, A, Bardari, S, Mattei, L, Ruocco, L, Boriani, G, Poli, D, Testa, S, Indolfi, C, Quintavalla, R, Mos, L, Ladyjanskaia, G, Aksoy, I, Van De Wetering, M, Theunissen, L, Den Hartog, F, Nijmeijer, R, Van De Wal, R, Reinders, S, Patterson, M, Melker, E, Troquay, R, Korecki, J, Szyszka, A, Diks, F, Sumis, J, Cygler, J, Miklaszewicz, B, Litwiejko-Pietrynczak, E, Napora, P, Drelich, G, Kawka-Urbanek, T, Wranicz, J, Mierzejewski, M, Drzewiecka, A, Wronska, D, Fares, I, Baska, J, Stania, K, Krzyzanowski, W, Miekus, P, Tyminski, M, Dronov, D, Zenin, S, Isaeva, E, Lopukhov, A, Yakusevich, V, Kuznetsov, D, Kameneva, T, Pokushalov, E, Karetnikova, V, Dik, I, Karpushina, I, Nikolin, D, Doletsky, A, Ardashev, A, Timofeeva, A, Miller, O, Lyamina, N, Shubik, Y, Boldueva, S, Blanco Coronado, J, Gonzalez Juanatey, C, Otero, E, Alonso, D, Torres Llergo, J, Gonzalez Lama, J, De Prada Tiffe, J, Garcia Seara, F, Gomez Doblas, J, Riancho, J, Clua-Espuny, J, Motero, J, Arrarte, V, Martin Raymondi, D, Isasti Aizpurua, G, Marin, F, Nieto, J, Fernandez Portales, J, Alvarez Garcia, P, Torstensson, I, Cederin, B, Kalm, T, Rosenqvist, U, Thulin, J, Hajimirsadeghi, A, Crisby, M, Manoj, A, Bakhai, A, Mistri, A, Krishnan, M, Kumar, S, Kirubakaran, S, Thomas, H, Camm, J, Ahmed, F, Ross, A, Barry, K, Stockwell, R, Broadley, A, Mamun, M, Chatterjee, K, Cooke, J, Mccready, J, Dutta, D, John, K, Pandya, P, Howlett, R, Vinson, P, Lim, Foley, P, Bruce, D, Dixit, A, Broughton, D, Taylor, J, Schilling, R, Leon, K, Saeed, K, Shaheen, S, Tawfik, M, Mortadda, A, Seleem, M, Aly, M, Kazamel, G, Elbadry, M, Kamal, S, Hassan, M, Mostafa, M, Medhat, M, Ekhlas, Ghaleb, R, Taha, M, Daoud, I, Al Din, H, Imam, A, El Hameed, M, Helmy, Al-Murayeh, M, Akhtar, N, Matto, B, Ghani, M, Amoudi, O, Morsy, M, Bashir, A, Al Hossni, Y, Al Ghamdi, B, Zia-Ul-Sabah, Mir, S, Dardir, D, Masswary, A, Al Shehri, A, Iqbal, J, Almansori, M, Venkitachalam, C, Kurian, J, Rao, J, Aisheh, A, Albawab, A, Subbaraman, B, Amanat, A, Esfehani, K, Lochan, R, Bin Brek, A, Mittal, B, Ghazi, Y, Krishna, M, Tabatabaei, S, Thoppil, P, Nasim, S, El Khider Nour, S, Barros, P, Almeida, A, Andrade, M, Garbelini, B, Silvestrini, T, Alves, A, De Lima, C, Kormann, A, De Lima, G, Halperin, C, Salvadori Junior, D, Freitas, A, Gemelli, J, Ornelas, C, Dantas, J, Aziz, J, Backes, L, Barroso, W, Paiva, M, De Figueiredo Neto, J, Dos Santos, F, De Lima Neto, J, Bergo, R, Salvador Junior, P, Lopez, A, Alva, J, Gamba, M, Padilla-Padilla, F, Ruiz, A, Berlingieri, J, Bakbak, A, Gupta, M, Saunders, K, Costa-Vitali, A, Beaudry, P, Bhargava, R, Khaykin, Y, Healey, J, Crystal, E, Nadeau, D, Begg, A, Anderson, C, Baveja, S, Cross, D, Catanchin, A, Brieger, D, Lim, K, Davidson, P, Tan, R, Bhindi, R, Hickey, J, Layland, J, Bloch, M, Itty, C, Singh, B, Carroll, P, Lee, A, Starmer, G, Lehman, R, Beyer-Westendorf J., Camm A. J., Fox K. A. A., Le Heuzey J. -Y., Haas S., Turpie A. G. G., Virdone S., Kakkar A. K., Pieper K. S., Kayani G., Gersh B. J., Hildebrandt P., Dominguez H., Comuth W., Frost L., Moller D. S., Christensen H., Bruun L. M., Milhem A., Gauthier J., Mielot C., Chanseaume S., Chopra S., Amlaiky A., Tricot O., Sierra V., Dompnier A., Zannad N., Pinzani A., Quatre A., Mansourati J., Fauchier L., Badenco N., Gandjbakhch E., Chachoua K. F., Malquarti V., Pierron F., Sacher F., Taieb J., Davy J. M., Marijon E., Lellouche N., Leenhardt A., Salem A., Lesto I., Muller J. J., Garcia R., Neau J. P., Berneau J. B., Schon N., Gulba D., Appel K. F., Merke J., Dshabrailov J., Bauknecht C., Scheuermann O., Schroder T., Jung W., Kopf A., Brachmann J., Leschke M., Taggeselle J., Seige M., Lassig T., Appel S., Schmiedl M., Muller K., Heinz G. U., Axthelm C., Eberhard K., Hugl B., Schwarz T., Sechtem U., Falanga A., Rubino V., Calo L., Ageno W., Massari F., Imberti D., Di Gennaro L., Gaita F., Margonato A., Cannava G., Capasso F., Diemberger I., Pelliccia F., Cafolla A., Bardari S., Mattei L., Ruocco L., Boriani G., Poli D., Testa S., Indolfi C., Quintavalla R., Mos L., Ladyjanskaia G., Aksoy I., Van De Wetering M., Theunissen L., Den Hartog F., Nijmeijer R., Van De Wal R., Reinders S., Patterson M., Melker E. D., Troquay R., Korecki J., Szyszka A., Diks F., Sumis J., Cygler J., Miklaszewicz B., Litwiejko-Pietrynczak E., Napora P., Drelich G., Kawka-Urbanek T., Wranicz J. K., Mierzejewski M., Drzewiecka A., Wronska D., Fares I., Baska J., Stania K., Krzyzanowski W., Miekus P., Tyminski M., Dronov D., Zenin S., Isaeva E., Lopukhov A., Yakusevich V., Kuznetsov D., Kameneva T., Pokushalov E., Karetnikova V., Dik I., Karpushina I., Nikolin D., Doletsky A., Ardashev A., Timofeeva A., Miller O., Lyamina N., Shubik Y., Boldueva S., Blanco Coronado J. L., Gonzalez Juanatey C., Otero E., Alonso D., Torres Llergo J., Gonzalez Lama J., De Prada Tiffe J. A. V., Garcia Seara F. J., Gomez Doblas J. J., Riancho J. A., Clua-Espuny J. L., Motero J., Arrarte V. I., Martin Raymondi D., Isasti Aizpurua G., Marin F., Nieto J. A., Fernandez Portales J., Alvarez Garcia P., Torstensson I., Cederin B., Kalm T., Rosenqvist U., Thulin J., Hajimirsadeghi A., Crisby M., Manoj A., Bakhai A., Mistri A., Krishnan M., Kumar S., Kirubakaran S., Thomas H., Camm J., Ahmed F., Ross A. M., Barry K., Stockwell R., Broadley A., Mamun M., Chatterjee K., Cooke J., McCready J., Dutta D., John K., Pandya P., Howlett R., Vinson P., Foley P., Bruce D., Dixit A., Broughton D., Taylor J., Schilling R., Leon K., Saeed K., Shaheen S., Tawfik M., Mortadda A., Seleem M., Aly M. S. I., Kazamel G., Elbadry M., Kamal S., Hassan M., Mostafa M., Medhat M. E. S., Ghaleb R., Taha M. O., Daoud I., Al Din H., Imam A. M., El Hameed M. A., Al-Murayeh M., Akhtar N., Matto B. M., Ghani M. A., Amoudi O. A., Morsy M. M., Bashir A. A. F., Al Hossni Y. M., Al Ghamdi B., Mir S., Dardir D., Masswary A., Al Shehri A. R., Iqbal J., Almansori M. A. J., Venkitachalam C. G., Kurian J., Rao J., Aisheh A., Albawab A. A., Subbaraman B., Amanat A., Esfehani K. J., Lochan R., Bin Brek A., Mittal B., Ghazi Y., Krishna M., Tabatabaei S. B., Thoppil P. S., Nasim S., El Khider Nour S., Barros P., Almeida A. P., Andrade M., Garbelini B., Silvestrini T. L., Alves A. R., De Lima C. E. B., Kormann A., De Lima G. G., Halperin C., Salvadori Junior D., Freitas A. F., Gemelli J. R., Ornelas C. E., Dantas J. M. M., Aziz J. L., Backes L. M., Barroso W. S., Paiva M. S., De Figueiredo Neto J. A., Dos Santos F. R., De Lima Neto J. A., Bergo R., Salvador Junior P. R., Lopez A. G., Alva J. C. P., Gamba M. A. A., Padilla-Padilla F. G., Ruiz A. E. B., Berlingieri J., Bakbak A., Gupta M., Saunders K., Costa-Vitali A., Beaudry P. R., Bhargava R., Khaykin Y., Healey J. S., Crystal E., Nadeau Dhillon, Begg A., Anderson C., Baveja S., Cross D., Catanchin A., Brieger D., Lim K. T., Davidson P., Tan R., Bhindi R., Hickey J., Layland J., Bloch M., Itty C., Singh B., Carroll P., Lee A., Starmer G., and Lehman R.
- Abstract
Background: Real-world data on non-vitamin K oral anticoagulants (NOACs) are essential in determining whether evidence from randomised controlled clinical trials translate into meaningful clinical benefits for patients in everyday practice. RIVER (RIVaroxaban Evaluation in Real life setting) is an ongoing international, prospective registry of patients with newly diagnosed non-valvular atrial fibrillation (NVAF) and at least one investigator-determined risk factor for stroke who received rivaroxaban as an initial treatment for the prevention of thromboembolic stroke. The aim of this paper is to describe the design of the RIVER registry and baseline characteristics of patients with newly diagnosed NVAF who received rivaroxaban as an initial treatment. Methods and results: Between January 2014 and June 2017, RIVER investigators recruited 5072 patients at 309 centres in 17 countries. The aim was to enroll consecutive patients at sites where rivaroxaban was already routinely prescribed for stroke prevention. Each patient is being followed up prospectively for a minimum of 2-years. The registry will capture data on the rate and nature of all thromboembolic events (stroke / systemic embolism), bleeding complications, all-cause mortality and other major cardiovascular events as they occur. Data quality is assured through a combination of remote electronic monitoring and onsite monitoring (including source data verification in 10% of cases). Patients were mostly enrolled by cardiologists (n = 3776, 74.6%), by internal medicine specialists 14.2% (n = 718) and by primary care/general practice physicians 8.2% (n = 417). The mean (SD) age of the population was 69.5 (11.0) years, 44.3% were women. Mean (SD) CHADS2 score was 1.9 (1.2) and CHA2DS2-VASc scores was 3.2 (1.6). Almost all patients (98.5%) were prescribed with once daily dose of rivaroxaban, most commonly 20 mg (76.5%) and 15 mg (20.0%) as their initial treatment; 17.9% of patients received concomitant antiplatelet the
- Published
- 2019
41. International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER)
- Author
-
Beyer-Westendorf, J., Camm, A. J., Fox, K. A. A., Le Heuzey, J. -Y., Haas, S., Turpie, A. G. G., Virdone, S., Kakkar, A. K., Pieper, K. S., Kayani, G., Gersh, B. J., Hildebrandt, P., Dominguez, H., Comuth, W., Frost, L., Moller, D. S., Christensen, H., Bruun, L. M., Milhem, A., Gauthier, J., Mielot, C., Chanseaume, S., Chopra, S., Amlaiky, A., Tricot, O., Sierra, V., Dompnier, A., Zannad, N., Pinzani, A., Quatre, A., Mansourati, J., Fauchier, L., Badenco, N., Gandjbakhch, E., Chachoua, K. F., Malquarti, V., Pierron, F., Sacher, F., Taieb, J., Davy, J. M., Marijon, E., Lellouche, N., Leenhardt, A., Salem, A., Lesto, I., Muller, J. J., Garcia, R., Neau, J. P., Berneau, J. B., Schon, N., Gulba, D., Appel, K. F., Merke, J., Dshabrailov, J., Bauknecht, C., Scheuermann, O., Schroder, T., Jung, W., Kopf, A., Brachmann, J., Leschke, M., Taggeselle, J., Seige, M., Lassig, T., Appel, S., Schmiedl, M., Muller, K., Heinz, G. U., Axthelm, C., Eberhard, K., Hugl, B., Schwarz, T., Sechtem, U., Falanga, A., Rubino, V., Calo, L., Ageno, W., Massari, F., Imberti, D., Di Gennaro, L., Gaita, F., Margonato, A., Cannava, G., Capasso, F., Diemberger, I., Pelliccia, F., Cafolla, A., Bardari, S., Mattei, L., Ruocco, L., Boriani, G., Poli, D., Testa, S., Indolfi, C., Quintavalla, R., Mos, L., Ladyjanskaia, G., Aksoy, I., Van De Wetering, M., Theunissen, L., Den Hartog, F., Nijmeijer, R., Van De Wal, R., Reinders, S., Patterson, M., Melker, E. D., Troquay, R., Korecki, J., Szyszka, A., Diks, F., Sumis, J., Cygler, J., Miklaszewicz, B., Litwiejko-Pietrynczak, E., Napora, P., Drelich, G., Kawka-Urbanek, T., Wranicz, J. K., Mierzejewski, M., Drzewiecka, A., Wronska, D., Fares, I., Baska, J., Stania, K., Krzyzanowski, W., Miekus, P., Tyminski, M., Dronov, D., Zenin, S., Isaeva, E., Lopukhov, A., Yakusevich, V., Kuznetsov, D., Kameneva, T., Pokushalov, E., Karetnikova, V., Dik, I., Karpushina, I., Nikolin, D., Doletsky, A., Ardashev, A., Timofeeva, A., Miller, O., Lyamina, N., Shubik, Y., Boldueva, S., Blanco Coronado, J. L., Gonzalez Juanatey, C., Otero, E., Alonso, D., Torres Llergo, J., Gonzalez Lama, J., De Prada Tiffe, J. A. V., Garcia Seara, F. J., Gomez Doblas, J. J., Riancho, J. A., Clua-Espuny, J. L., Motero, J., Arrarte, V. I., Martin Raymondi, D., Isasti Aizpurua, G., Marin, F., Nieto, J. A., Fernandez Portales, J., Alvarez Garcia, P., Torstensson, I., Cederin, B., Kalm, T., Rosenqvist, U., Thulin, J., Hajimirsadeghi, A., Crisby, M., Manoj, A., Bakhai, A., Mistri, A., Krishnan, M., Kumar, S., Kirubakaran, S., Thomas, H., Camm, J., Ahmed, F., Ross, A. M., Barry, K., Stockwell, R., Broadley, A., Mamun, M., Chatterjee, K., Cooke, J., Mccready, J., Dutta, D., John, K., Pandya, P., Howlett, R., Vinson, P., Lim, Foley, P., Bruce, D., Dixit, A., Broughton, D., Taylor, J., Schilling, R., Leon, K., Saeed, K., Shaheen, S., Tawfik, M., Mortadda, A., Seleem, M., Aly, M. S. I., Kazamel, G., Elbadry, M., Kamal, S., Hassan, M., Mostafa, M., Medhat, M. E. S., Ekhlas, Ghaleb, R., Taha, M. O., Daoud, I., Al Din, H., Imam, A. M., El Hameed, M. A., Helmy, Al-Murayeh, M., Akhtar, N., Matto, B. M., Ghani, M. A., Amoudi, O. A., Morsy, M. M., Bashir, A. A. F., Al Hossni, Y. M., Al Ghamdi, B., Zia-Ul-Sabah, Mir, S., Dardir, D., Masswary, A., Al Shehri, A. R., Iqbal, J., Almansori, M. A. J., Venkitachalam, C. G., Kurian, J., Rao, J., Aisheh, A., Albawab, A. A., Subbaraman, B., Amanat, A., Esfehani, K. J., Lochan, R., Bin Brek, A., Mittal, B., Ghazi, Y., Krishna, M., Tabatabaei, S. B., Thoppil, P. S., Nasim, S., El Khider Nour, S., Barros, P., Almeida, A. P., Andrade, M., Garbelini, B., Silvestrini, T. L., Alves, A. R., De Lima, C. E. B., Kormann, A., De Lima, G. G., Halperin, C., Salvadori Junior, D., Freitas, A. F., Gemelli, J. R., Ornelas, C. E., Dantas, J. M. M., Aziz, J. L., Backes, L. M., Barroso, W. S., Paiva, M. S., De Figueiredo Neto, J. A., Dos Santos, F. R., De Lima Neto, J. A., Bergo, R., Salvador Junior, P. R., Lopez, A. G., Alva, J. C. P., Gamba, M. A. A., Padilla-Padilla, F. G., Ruiz, A. E. B., Berlingieri, J., Bakbak, A., Gupta, M., Saunders, K., Costa-Vitali, A., Beaudry, P. R., Bhargava, R., Khaykin, Y., Healey, J. S., Crystal, E., Nadeau, Dhillon, Begg, A., Anderson, C., Baveja, S., Cross, D., Catanchin, A., Brieger, D., Lim, K. T., Davidson, P., Tan, R., Bhindi, R., Hickey, J., Layland, J., Bloch, M., Itty, C., Singh, B., Carroll, P., Lee, A., Starmer, G., Lehman, R., Universidad de Cantabria, Beyer-Westendorf J., Camm A.J., Fox K.A.A., Le Heuzey J.-Y., Haas S., Turpie A.G.G., Virdone S., Kakkar A.K., RIVER Registry Investigators: [..], A. Falanga, V. Rubino, L. Calo, W. Ageno, F. Massari, D. Imberti, L. Di Gennaro, F. Gaita, A. Margonato, G. Cannava, F. Capasso, I. Diemberger, F. Pelliccia, A. Cafolla, S. Bardari, L. Mattei, L. Ruocco, G. Boriani, D. Poli, S. Testa, C. Indolfi, R. Quintavalla, L. Mo, .., Beyer-Westendorf, J, Camm, A, Fox, K, Le Heuzey, J, Haas, S, Turpie, A, Virdone, S, Kakkar, A, Pieper, K, Kayani, G, Gersh, B, Hildebrandt, P, Dominguez, H, Comuth, W, Frost, L, Moller, D, Christensen, H, Bruun, L, Milhem, A, Gauthier, J, Mielot, C, Chanseaume, S, Chopra, S, Amlaiky, A, Tricot, O, Sierra, V, Dompnier, A, Zannad, N, Pinzani, A, Quatre, A, Mansourati, J, Fauchier, L, Badenco, N, Gandjbakhch, E, Chachoua, K, Malquarti, V, Pierron, F, Sacher, F, Taieb, J, Davy, J, Marijon, E, Lellouche, N, Leenhardt, A, Salem, A, Lesto, I, Muller, J, Garcia, R, Neau, J, Berneau, J, Schon, N, Gulba, D, Appel, K, Merke, J, Dshabrailov, J, Bauknecht, C, Scheuermann, O, Schroder, T, Jung, W, Kopf, A, Brachmann, J, Leschke, M, Taggeselle, J, Seige, M, Lassig, T, Appel, S, Schmiedl, M, Muller, K, Heinz, G, Axthelm, C, Eberhard, K, Hugl, B, Schwarz, T, Sechtem, U, Falanga, A, Rubino, V, Calo, L, Ageno, W, Massari, F, Imberti, D, Di Gennaro, L, Gaita, F, Margonato, A, Cannava, G, Capasso, F, Diemberger, I, Pelliccia, F, Cafolla, A, Bardari, S, Mattei, L, Ruocco, L, Boriani, G, Poli, D, Testa, S, Indolfi, C, Quintavalla, R, Mos, L, Ladyjanskaia, G, Aksoy, I, Van De Wetering, M, Theunissen, L, Den Hartog, F, Nijmeijer, R, Van De Wal, R, Reinders, S, Patterson, M, Melker, E, Troquay, R, Korecki, J, Szyszka, A, Diks, F, Sumis, J, Cygler, J, Miklaszewicz, B, Litwiejko-Pietrynczak, E, Napora, P, Drelich, G, Kawka-Urbanek, T, Wranicz, J, Mierzejewski, M, Drzewiecka, A, Wronska, D, Fares, I, Baska, J, Stania, K, Krzyzanowski, W, Miekus, P, Tyminski, M, Dronov, D, Zenin, S, Isaeva, E, Lopukhov, A, Yakusevich, V, Kuznetsov, D, Kameneva, T, Pokushalov, E, Karetnikova, V, Dik, I, Karpushina, I, Nikolin, D, Doletsky, A, Ardashev, A, Timofeeva, A, Miller, O, Lyamina, N, Shubik, Y, Boldueva, S, Blanco Coronado, J, Gonzalez Juanatey, C, Otero, E, Alonso, D, Torres Llergo, J, Gonzalez Lama, J, De Prada Tiffe, J, Garcia Seara, F, Gomez Doblas, J, Riancho, J, Clua-Espuny, J, Motero, J, Arrarte, V, Martin Raymondi, D, Isasti Aizpurua, G, Marin, F, Nieto, J, Fernandez Portales, J, Alvarez Garcia, P, Torstensson, I, Cederin, B, Kalm, T, Rosenqvist, U, Thulin, J, Hajimirsadeghi, A, Crisby, M, Manoj, A, Bakhai, A, Mistri, A, Krishnan, M, Kumar, S, Kirubakaran, S, Thomas, H, Camm, J, Ahmed, F, Ross, A, Barry, K, Stockwell, R, Broadley, A, Mamun, M, Chatterjee, K, Cooke, J, Mccready, J, Dutta, D, John, K, Pandya, P, Howlett, R, Vinson, P, Lim, Foley, P, Bruce, D, Dixit, A, Broughton, D, Taylor, J, Schilling, R, Leon, K, Saeed, K, Shaheen, S, Tawfik, M, Mortadda, A, Seleem, M, Aly, M, Kazamel, G, Elbadry, M, Kamal, S, Hassan, M, Mostafa, M, Medhat, M, Ekhlas, Ghaleb, R, Taha, M, Daoud, I, Al Din, H, Imam, A, El Hameed, M, Helmy, Al-Murayeh, M, Akhtar, N, Matto, B, Ghani, M, Amoudi, O, Morsy, M, Bashir, A, Al Hossni, Y, Al Ghamdi, B, Zia-Ul-Sabah, Mir, S, Dardir, D, Masswary, A, Al Shehri, A, Iqbal, J, Almansori, M, Venkitachalam, C, Kurian, J, Rao, J, Aisheh, A, Albawab, A, Subbaraman, B, Amanat, A, Esfehani, K, Lochan, R, Bin Brek, A, Mittal, B, Ghazi, Y, Krishna, M, Tabatabaei, S, Thoppil, P, Nasim, S, El Khider Nour, S, Barros, P, Almeida, A, Andrade, M, Garbelini, B, Silvestrini, T, Alves, A, De Lima, C, Kormann, A, De Lima, G, Halperin, C, Salvadori Junior, D, Freitas, A, Gemelli, J, Ornelas, C, Dantas, J, Aziz, J, Backes, L, Barroso, W, Paiva, M, De Figueiredo Neto, J, Dos Santos, F, De Lima Neto, J, Bergo, R, Salvador Junior, P, Lopez, A, Alva, J, Gamba, M, Padilla-Padilla, F, Ruiz, A, Berlingieri, J, Bakbak, A, Gupta, M, Saunders, K, Costa-Vitali, A, Beaudry, P, Bhargava, R, Khaykin, Y, Healey, J, Crystal, E, Nadeau, D, Begg, A, Anderson, C, Baveja, S, Cross, D, Catanchin, A, Brieger, D, Lim, K, Davidson, P, Tan, R, Bhindi, R, Hickey, J, Layland, J, Bloch, M, Itty, C, Singh, B, Carroll, P, Lee, A, Starmer, G, Lehman, R, Beyer-Westendorf, J., Camm, A. J., Fox, K. A. A., Le Heuzey, J. -Y., Haas, S., Turpie, A. G. G., Virdone, S., Kakkar, A. K., Pieper, K. S., Kayani, G., Gersh, B. J., Hildebrandt, P., Dominguez, H., Comuth, W., Frost, L., Moller, D. S., Christensen, H., Bruun, L. M., Milhem, A., Gauthier, J., Mielot, C., Chanseaume, S., Chopra, S., Amlaiky, A., Tricot, O., Sierra, V., Dompnier, A., Zannad, N., Pinzani, A., Quatre, A., Mansourati, J., Fauchier, L., Badenco, N., Gandjbakhch, E., Chachoua, K. F., Malquarti, V., Pierron, F., Sacher, F., Taieb, J., Davy, J. M., Marijon, E., Lellouche, N., Leenhardt, A., Salem, A., Lesto, I., Muller, J. J., Garcia, R., Neau, J. P., Berneau, J. B., Schon, N., Gulba, D., Appel, K. F., Merke, J., Dshabrailov, J., Bauknecht, C., Scheuermann, O., Schroder, T., Jung, W., Kopf, A., Brachmann, J., Leschke, M., Taggeselle, J., Seige, M., Lassig, T., Appel, S., Schmiedl, M., Muller, K., Heinz, G. U., Axthelm, C., Eberhard, K., Hugl, B., Schwarz, T., Sechtem, U., Falanga, A., Rubino, V., Calo, L., Ageno, W., Massari, F., Imberti, D., Di Gennaro, L., Gaita, F., Margonato, A., Cannava, G., Capasso, F., Diemberger, I., Pelliccia, F., Cafolla, A., Bardari, S., Mattei, L., Ruocco, L., Boriani, G., Poli, D., Testa, S., Indolfi, C., Quintavalla, R., Mos, L., Ladyjanskaia, G., Aksoy, I., Van De Wetering, M., Theunissen, L., Den Hartog, F., Nijmeijer, R., Van De Wal, R., Reinders, S., Patterson, M., Melker, E. D., Troquay, R., Korecki, J., Szyszka, A., Diks, F., Sumis, J., Cygler, J., Miklaszewicz, B., Litwiejko-Pietrynczak, E., Napora, P., Drelich, G., Kawka-Urbanek, T., Wranicz, J. K., Mierzejewski, M., Drzewiecka, A., Wronska, D., Fares, I., Baska, J., Stania, K., Krzyzanowski, W., Miekus, P., Tyminski, M., Dronov, D., Zenin, S., Isaeva, E., Lopukhov, A., Yakusevich, V., Kuznetsov, D., Kameneva, T., Pokushalov, E., Karetnikova, V., Dik, I., Karpushina, I., Nikolin, D., Doletsky, A., Ardashev, A., Timofeeva, A., Miller, O., Lyamina, N., Shubik, Y., Boldueva, S., Blanco Coronado, J. L., Gonzalez Juanatey, C., Otero, E., Alonso, D., Torres Llergo, J., Gonzalez Lama, J., De Prada Tiffe, J. A. V., Garcia Seara, F. J., Gomez Doblas, J. J., Riancho, J. A., Clua-Espuny, J. L., Motero, J., Arrarte, V. I., Martin Raymondi, D., Isasti Aizpurua, G., Marin, F., Nieto, J. A., Fernandez Portales, J., Alvarez Garcia, P., Torstensson, I., Cederin, B., Kalm, T., Rosenqvist, U., Thulin, J., Hajimirsadeghi, A., Crisby, M., Manoj, A., Bakhai, A., Mistri, A., Krishnan, M., Kumar, S., Kirubakaran, S., Thomas, H., Camm, J., Ahmed, F., Ross, A. M., Barry, K., Stockwell, R., Broadley, A., Mamun, M., Chatterjee, K., Cooke, J., Mccready, J., Dutta, D., John, K., Pandya, P., Howlett, R., Vinson, P., Foley, P., Bruce, D., Dixit, A., Broughton, D., Taylor, J., Schilling, R., Leon, K., Saeed, K., Shaheen, S., Tawfik, M., Mortadda, A., Seleem, M., Aly, M. S. I., Kazamel, G., Elbadry, M., Kamal, S., Hassan, M., Mostafa, M., Medhat, M. E. S., Ghaleb, R., Taha, M. O., Daoud, I., Al Din, H., Imam, A. M., El Hameed, M. A., Al-Murayeh, M., Akhtar, N., Matto, B. M., Ghani, M. A., Amoudi, O. A., Morsy, M. M., Bashir, A. A. F., Al Hossni, Y. M., Al Ghamdi, B., Mir, S., Dardir, D., Masswary, A., Al Shehri, A. R., Iqbal, J., Almansori, M. A. J., Venkitachalam, C. G., Kurian, J., Rao, J., Aisheh, A., Albawab, A. A., Subbaraman, B., Amanat, A., Esfehani, K. J., Lochan, R., Bin Brek, A., Mittal, B., Ghazi, Y., Krishna, M., Tabatabaei, S. B., Thoppil, P. S., Nasim, S., El Khider Nour, S., Barros, P., Almeida, A. P., Andrade, M., Garbelini, B., Silvestrini, T. L., Alves, A. R., De Lima, C. E. B., Kormann, A., De Lima, G. G., Halperin, C., Salvadori Junior, D., Freitas, A. F., Gemelli, J. R., Ornelas, C. E., Dantas, J. M. M., Aziz, J. L., Backes, L. M., Barroso, W. S., Paiva, M. S., De Figueiredo Neto, J. A., Dos Santos, F. R., De Lima Neto, J. A., Bergo, R., Salvador Junior, P. R., Lopez, A. G., Alva, J. C. P., Gamba, M. A. A., Padilla-Padilla, F. G., Ruiz, A. E. B., Berlingieri, J., Bakbak, A., Gupta, M., Saunders, K., Costa-Vitali, A., Beaudry, P. R., Bhargava, R., Khaykin, Y., Healey, J. S., Crystal, E., Nadeau, Dhillon, Begg, A., Anderson, C., Baveja, S., Cross, D., Catanchin, A., Brieger, D., Lim, K. T., Davidson, P., Tan, R., Bhindi, R., Hickey, J., Layland, J., Bloch, M., Itty, C., Singh, B., Carroll, P., Lee, A., Starmer, G., and Lehman, R.
- Subjects
medicine.medical_specialty ,Registry ,medicine.drug_class ,Population ,Thromboembolic stroke ,Outcomes ,030204 cardiovascular system & hematology ,03 medical and health sciences ,0302 clinical medicine ,Antithrombotic ,Rivaroxaban ,Anticoagulant ,Atrial fibrillation ,medicine ,030212 general & internal medicine ,Risk factor ,education ,Stroke ,Outcome ,education.field_of_study ,business.industry ,lcsh:RC633-647.5 ,Research ,Hematology ,lcsh:Diseases of the blood and blood-forming organs ,medicine.disease ,ddc ,Clinical trial ,Emergency medicine ,business ,medicine.drug - Abstract
Background: Real-world data on non-vitamin K oral anticoagulants (NOACs) are essential in determining whether evidence from randomised controlled clinical trials translate into meaningful clinical benefits for patients in everyday practice. RIVER (RIVaroxaban Evaluation in Real life setting) is an ongoing international, prospective registry of patients with newly diagnosed non-valvular atrial fibrillation (NVAF) and at least one investigator-determined risk factor for stroke who received rivaroxaban as an initial treatment for the prevention of thromboembolic stroke. The aim of this paper is to describe the design of the RIVER registry and baseline characteristics of patients with newly diagnosed NVAF who received rivaroxaban as an initial treatment. Methods and results: Between January 2014 and June 2017, RIVER investigators recruited 5072 patients at 309 centres in 17 countries. The aim was to enroll consecutive patients at sites where rivaroxaban was already routinely prescribed for stroke prevention. Each patient is being followed up prospectively for a minimum of 2-years. The registry will capture data on the rate and nature of all thromboembolic events (stroke / systemic embolism), bleeding complications, all-cause mortality and other major cardiovascular events as they occur. Data quality is assured through a combination of remote electronic monitoring and onsite monitoring (including source data verification in 10% of cases). Patients were mostly enrolled by cardiologists (n = 3776, 74.6%), by internal medicine specialists 14.2% (n = 718) and by primary care/general practice physicians 8.2% (n = 417). The mean (SD) age of the population was 69.5 (11.0) years, 44.3% were women. Mean (SD) CHADS2 score was 1.9 (1.2) and CHA2DS2-VASc scores was 3.2 (1.6). Almost all patients (98.5%) were prescribed with once daily dose of rivaroxaban, most commonly 20 mg (76.5%) and 15 mg (20.0%) as their initial treatment; 17.9% of patients received concomitant antiplatelet therapy. Most patients enrolled in RIVER met the recommended threshold for AC therapy (86.6% for 2012 ESC Guidelines, and 79.8% of patients according to 2016 ESC Guidelines). Conclusions: The RIVER prospective registry will expand our knowledge of how rivaroxaban is prescribed in everyday practice and whether evidence from clinical trials can be translated to the broader cross-section of patients in the real world. Funding: This work is supported by an unrestricted research grant from Bayer AG (Berlin, Germany) to the Thrombosis Research Institute (London, UK), which sponsors the RIVER registry. The funding source had no involvement in the data collection, data analysis or data interpretation.
- Published
- 2019
42. Grey zones on valvular heart disease: Interventional cardiology versus cardiac surgery. Expert opinion [Grey zones sulla cardiologia interventistica valvolare e cardiochirurgia a confronto. Opinioni degli esperti]
- Author
-
Frigerio M, Fiocca L, Bedogni F, Alfieri O, Margonato A, Galletti L, Indolfi C, Senni M, Grigioni F, Frigerio, M, Fiocca, L, Bedogni, F, Alfieri, O, Margonato, A, Galletti, L, Indolfi, C, Senni, M, and Grigioni, F
- Subjects
Transcatheter aortic valve implantation ,Aortic stenosi ,MitraClip ,Guideline ,Valvular heart disease ,Mitral regurgitation - Abstract
Clinical guidelines, while representing an objective reference to perform correct therapeutic choices, contain grey zones, where recommendations are not supported by solid evidence. In a conference held in Bergamo in October 2018, an attempt was made to highlight some of the main grey zones in Cardiology and, through a comparison between experts, to draw shared conclusions that can illuminate our clinical practice. This manuscript contains the statements of the symposium concerning the controversies in the percutaneous treatment of valvulopathies. The first topic concerns the durability of aortic bioprostheses, comparing percutaneous interventional with surgical experiences. The second issue examines the opportunity to extend percutaneous aortic replacement as standard care to low-risk patients. The last gap in evidence concerns the percutaneous treatment of functional mitral valve insufficiency, with the MitraClip system. The work has also been implemented with evidences deriving from important randomized studies published after the date of the Conference.
- Published
- 2020
43. le complicanze cardiologiche
- Author
-
Spaccarotella C, Mongiardo A, De Rosa S, Indolfi C, Prof. Carlo Torti, Spaccarotella, C, Mongiardo, A, De Rosa, S, and Indolfi, C
- Published
- 2020
44. Grey zones on valvular heart disease: Interventional cardiology versus cardiac surgery. Expert opinion
- Author
-
Frigerio M., Fiocca L., Bedogni F., Alfieri O., Margonato A., Galletti L., Indolfi C., Senni M., Grigioni F., Frigerio, M., Fiocca, L., Bedogni, F., Alfieri, O., Margonato, A., Galletti, L., Indolfi, C., Senni, M., and Grigioni, F.
- Subjects
Transcatheter aortic valve implantation ,Aortic stenosi ,MitraClip ,Guideline ,Valvular heart disease ,Mitral regurgitation - Abstract
Clinical guidelines, while representing an objective reference to perform correct therapeutic choices, contain grey zones, where recommendations are not supported by solid evidence. In a conference held in Bergamo in October 2018, an attempt was made to highlight some of the main grey zones in Cardiology and, through a comparison between experts, to draw shared conclusions that can illuminate our clinical practice. This manuscript contains the statements of the symposium concerning the controversies in the percutaneous treatment of valvulopathies. The first topic concerns the durability of aortic bioprostheses, comparing percutaneous interventional with surgical experiences. The second issue examines the opportunity to extend percutaneous aortic replacement as standard care to low-risk patients. The last gap in evidence concerns the percutaneous treatment of functional mitral valve insufficiency, with the MitraClip system. The work has also been implemented with evidences deriving from important randomized studies published after the date of the Conference.
- Published
- 2020
45. Le valvulopatie
- Author
-
Spaccarotella C, Montisci R, Scipione Carerj, Esposito L, Dell'Aversana S, A Mongiardo, Pilato E, Indolfi C, Pasquale Perrone Filardi, Paola Gargiulo, Stefania Paolillo, Spaccarotella, C, Montisci, R, Scipione, Carerj, Esposito, L, Dell'Aversana, S, A, Mongiardo, Pilato, E, and Indolfi, C
- Published
- 2020
46. Angioplasty in chronic coronary syndromes after the ISCHEMIA trial: What's new? - The interventional cardiologist's point of view
- Author
-
Indolfi C., Spaccarotella C., Indolfi, C., and Spaccarotella, C.
- Subjects
Myocardial Ischemia ,Myocardial Revascularization ,Angina, Stable ,Cardiologist ,Angioplasty, Balloon, Coronary ,Human ,Randomized Controlled Trials as Topic - Published
- 2020
47. Appropriateness criteria for the management of lipid-lowering therapy with alirocumab in high cardiovascular risk patients. The opinion of a multidisciplinary group of Italian experts
- Author
-
Lettino, M., Zambon, A., Musumeci, G., Arca, M., Bilato, C., Brunetti, N. D., Calabro, P., Casu, G., Chiarella, F., Faggiano, P., Ferlini, M., Guardigli, G., Imbalzano, E., Indolfi, C., Marcucci, R., Menozzi, A., Mureddu, G. F., Filardi, P. P., Pirro, M., Pisciotta, L., Scherillo, M., Suppressa, P., Uguccioni, M., Varbella, F., Gentile, L., Rapezzi, C., Averna, M., Lettino, Maddalena, Zambon, Alberto, Musumeci, Giuseppe, Arca, Marcello, Bilato, Claudio, Brunetti, Natale Daniele, Calabrò, Paolo, Casu, Gavino, Chiarella, Francesco, Faggiano, Pompilio, Ferlini, Marco, Guardigli, Gabriele, Imbalzano, Egidio, Indolfi, Ciro, Marcucci, Rossella, Menozzi, Alberto, Mureddu, Gian Francesco, Filardi, Pasquale Perrone, Pirro, Matteo, Pisciotta, Livia, Scherillo, Marino, Suppressa, Patrizia, Uguccioni, Massimo, Varbella, Ferdinando, Gentile, Luigi, Rapezzi, Claudio, Averna, Maurizio, Lettino M., Zambon A., Musumeci G., Arca M., Bilato C., Brunetti N.D., Calabro P., Casu G., Chiarella F., Faggiano P., Ferlini M., Guardigli G., Imbalzano E., Indolfi C., Marcucci R., Menozzi A., Mureddu G.F., Filardi P.P., Pirro M., Pisciotta L., Scherillo M., Suppressa P., Uguccioni M., Varbella F., Gentile L., Rapezzi C., and Averna M.
- Subjects
Settore MED/09 - Medicina Interna ,Consensus ,PCSK9 inhibitor ,Familial hypercholesterolemia ,Hypercholesterolemia ,Antibodies, Monoclonal, Humanized ,Anticholesteremic Agents ,Atherosclerosis ,Cholesterol, LDL ,Humans ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,Italy ,Risk Assessment ,Risk Factors ,Cardiovascular Diseases ,Consensu ,Antibodies ,LDL ,Acute coronary syndrome ,Alirocumab ,Cardiovascular risk ,PCSK9 inhibitors ,Anticholesteremic Agent ,Monoclonal ,Humanized ,Cholesterol ,Atherosclerosi - Abstract
High levels of LDL cholesterol (LDL-C) represent a causal factor for cardiovascular diseases on an atherosclerotic basis, with a direct correlation between these and mortality or cardiovascular events, such that the reduction of both is associated proportionally and linearly with the reduction of LDL-C.Statins and ezetimibe are used for LDL-C lowering but may not be sufficient to achieve the targets defined by the ESC/EAS guidelines, which recommend use of PCSK9 inhibitors for further LDL-C reduction in patients not at goal.This project submitted 86 clinical scenarios to a group of experts, cardiologists, internists and lipidologists, collecting their opinion on the appropriateness of different behaviors and decisions. We used the RAND/UCLA method of assessing the appropriateness of clinical interventions, validated to combine the best scientific evidence available with expert judgment. To this end, the benefit-risk ratio was evaluated in the proposed clinical scenarios. Each indication was classified as "appropriate", "uncertain" or "inappropriate" based on the average score given by the participants.This document presents the results of a consensus process that led to the development of recommendations for the management of clinical scenarios on the treatment of patients with dyslipidemia, which cannot always be solved with scientific evidence alone.
- Published
- 2020
48. Mechanisms of Benefit in the Ischemic Myocardium due to Heart Rate Reduction
- Author
-
Guth, Brain D., Indolfi, C., Heusch, G., Seitelberger, R., Ross, J., Jr., Heusch, Gerd, editor, and Ross, John, Jr., editor
- Published
- 1991
- Full Text
- View/download PDF
49. Changes in Left atrial strain in patients with aortic stenosis after TAVI
- Author
-
Leo, I, primary, Sabatino, J, additional, Strangio, A, additional, Polimeni, A, additional, Sorrentino, S, additional, Mongiardo, A, additional, Spaccarotella, C A M, additional, Purri, I, additional, De Rosa, S, additional, and Indolfi, C, additional
- Published
- 2021
- Full Text
- View/download PDF
50. Assessment of intracardiac flow dynamics for the evaluation of patients with different ventricular geometry
- Author
-
Leo, I, primary, Sabatino, J, additional, Strangio, A, additional, Maglione, M, additional, Troilo, F, additional, Loliva, G, additional, Canino, G, additional, Critelli, C, additional, De Rosa, S, additional, and Indolfi, C, additional
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.